51
|
Shetty AA, Kim SJ, Ahmed S, Trattnig S, Kim SA, Jang HJ. A cost-effective cell- and matrix-based minimally invasive single-stage chondroregenerative technique developed with validated vertical translation methodology. Ann R Coll Surg Engl 2018; 100:240-246. [PMID: 29493355 DOI: 10.1308/rcsann.2017.0223] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Introduction The morbidity and significant health economic impact associated with the chondral lesion has led to a large number of strategies for therapeutic neochondrogenesis. The challenge has been to develop techniques that are cost effective single-stage procedures with minimal surgical trauma that have undergone rigorous preclinical scrutiny and robust reproducible assessment of effectiveness. A biological repair requires the generation of a cellular and matrix composite with appropriate signalling for chondrogenic differentiation. Methods and results A technique was developed that allowed chondrogenic primary (uncultured) cells from bone marrow aspirate concentrate, combined with a composite hydrophilic and fibrillar matrix to be applied arthroscopically to a site of a chondral lesion. The construct was tested in vitro and in animal experiments before clinical trials. Clinical trials involved 60 patients in a prospective study. Symptomatic International Cartilage Repair Society grade 3 and 4a lesions were mapped and treated. Pre- and postoperative clinical assessments showed statistically significant improved outcomes; Lysholm Knee Scoring Scale (mean 52.8 to > 76.4; P < 0.05) International Knee Documentation Committee (mean 39 to > 79 P < 0.05) and Knee injury and Osteoarthritis Outcome Score (64.5 to >89.2 P < 0.05). Postoperative magnetic resonance imaging was evaluated morphologically (magnetic resonance observation of cartilage repair tissue, average MOCART score 72) and qualitatively; the regenerate was comparable to native cartilage. Conclusions This technique is effective, affordable, requires no complex tools and delivers a single-stage treatment that is potentially accessible to any centre capable of performing arthroscopic surgery. Good clinical results were found to be sustained at five years of follow-up with a regenerate that appears hyaline like using multiple magnetic resonance measures.
Collapse
Affiliation(s)
- A A Shetty
- Institute of Medical Sciences, Faculty of Health and Social Sciences, Canterbury Christ Church University , Chatham Maritime , UK
| | - S J Kim
- Department of Orthopaedic Surgery, College of Medicine, Catholic University of Korea , Gyeonggi-do , Republic of Korea
| | - S Ahmed
- Institute of Medical Sciences, Faculty of Health and Social Sciences, Canterbury Christ Church University , Chatham Maritime , UK
| | - S Trattnig
- MR Centre - High-field MR, Department of Radiology, Medical University of Vienna , Vienna , Austria
| | - S A Kim
- Department of Orthopaedic Surgery, College of Medicine, Catholic University of Korea , Gyeonggi-do , Republic of Korea
| | - H J Jang
- Department of Orthopaedic Surgery, College of Medicine, Catholic University of Korea , Gyeonggi-do , Republic of Korea
| |
Collapse
|
52
|
Kim YM, Ha AN, Kim JW, Kim SJ. Double-blind Randomized Study to Evaluate the Safety and Efficacy of Over-the-counter Tooth-whitening Agents Containing 2.9% Hydrogen Peroxide. Oper Dent 2018. [PMID: 29513635 DOI: 10.2341/16-379-c] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES In this double-blind randomized study, we evaluated the safety and efficacy of over-the-counter (OTC) bleaching products that included 2.9% hydrogen peroxide (H2O2) with two methods of application: strip and paint-on. METHODS AND MATERIALS A commonly used product was selected for each type (strip and paint-on) of OTC bleaching agent. In total, 75 volunteers were assigned randomly into five groups: two test groups (strip and paint-on), two negative control groups (products without H2O2), and one positive control group (dentist-supervised home bleaching). The tooth shade was evaluated with a spectrophotometer and Vita shade guide at baseline and 2 weeks and 4 weeks after use. To document any adverse reactions, such as hypersensitivity or tissue irritation, all patients were examined and the Gingival Index (GI), Plaque Index (PI), and a visual analog scale (VAS) measuring the cold response were obtained. RESULTS There were significant differences among the five groups ( p<0.001). The positive control showed the greatest color changes; then, in decreasing order, the strip-type test group, paint-on-type test group, and negative controls. The strip-type bleaching agent was significantly more effective than the paint-on-type agent and the negative control, while it was significantly less effective than the dentist-supervised home bleaching. Regardless of the treatment group, the canines showed greater color changes than did the central or lateral incisors. Some cases of gingival irritation and hypersensitivity were observed, but they were mild and reversible. GI, PI, and VAS scores were not significantly changed. CONCLUSIONS Within the limitations of this study, the results indicated that the strip-type and paint-on-type OTC bleaching agents were significantly less efficacious than was dentist-supervised home bleaching; however, they showed acceptable safety and efficacy. The strip-type was more effective than was the paint-on-type in this study.
Collapse
|
53
|
Affiliation(s)
- J S Park
- Dong-A University, College of Medicine, Busan, Korea Republic of
| | - D H Lee
- Dong-A University, College of Medicine, Busan, Korea Republic of
| | - S J Kim
- Dong-A University, College of Medicine, Busan, Korea Republic of
| |
Collapse
|
54
|
Abstract
BACKGROUND Despite the increasing population of elderly individuals in Korea, there are no evidence-based geriatric nursing practice guidelines. AIM This study aimed to identify and prioritize topics related to the development of evidence-based geriatric nursing practice guidelines in long-term care facilities in Korea. METHODS To identify potential topics, 89 nurses responded to a questionnaire on activities that require further evidence and/or standardization in the long-term care facility setting. To prioritize these topics, 14 geriatric nursing experts completed surveys to prioritize five categories. RESULTS The collected data included 240 clinical topics, which were classified into 41 subcategories and 18 main categories. According to topic prioritization by the geriatric nursing experts, the following were the most heavily weighted categories: fall prevention, position change and prevention of pressure ulcers. CONCLUSIONS The development of standardized guidelines based on these results may help improve the quality of geriatric care and quality of life of older individuals. The small number of respondents may be a limitation of this study, and further study is needed to expand the population. IMPLICATIONS FOR NURSING AND HEALTH POLICY The development of evidence-based nursing guidelines based on the present findings will help improve the quality of nursing in long-term care facilities. Additionally, health policies and systems, such as introduction of a fee for nursing services for older individuals based on the evidence, are worth considering.
Collapse
Affiliation(s)
- S Kim
- Department of Nursing, Changwon National University, Changwon, Korea
| | - K Kim
- Department of Nursing, Chung-Ang University, Seoul, Korea
| | - S J Kim
- Seoul Seniors Tower, Seoul, Korea
| |
Collapse
|
55
|
Park H, Park JB, Kim JH, Lee KW, Lee HS, Kim GS, Shin DY, Oh SH, Jin SM, Kim SJ. Simultaneous Subtotal Pancreatectomy and Streptozotocin Injection for Diabetes Modeling in Cynomolgus Monkeys. Transplant Proc 2018; 49:1142-1149. [PMID: 28583545 DOI: 10.1016/j.transproceed.2017.03.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND In an experimental animal model of islet transplantation, stable induction of insulin-dependent diabetes mellitus (IDDM) and islet isolation from donor pancreas are essential. Total pancreatectomy for IDDM induction and islet procurement in nonhuman primates leads to unwanted loss of exocrine function and may lead to morbidities associated with IDDM. METHODS IDDM induction with streptozotocin (STZ) is associated with drug toxicity of STZ and necessitates the killing of another animal for islet procurement. In this study, we performed a subtotal pancreatectomy combined with reduced STZ injection to induce IDDM and procure islets in a nonhuman primate model. RESULTS Twelve cynomolgus monkeys received low-dose STZ injections (60 mg/kg) simultaneously with subtotal pancreatectomy. All monkeys recovered from the procedure without complications. IDDM was induced in the animals. 57,691 ± 16,050 islets were isolated from the resected pancreas and transplanted into other monkeys. CONCLUSIONS Simultaneous subtotal pancreatectomy and low-dose STZ injection represent an effective and safe method to create an animal model of insulin dependence diabetes, while at the same time providing sufficient amounts of fresh islet cells for allotransplantation without requiring killing of additional animals.
Collapse
Affiliation(s)
- H Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J B Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
| | - J H Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
| | - K W Lee
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H S Lee
- Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, Korea
| | - G-S Kim
- Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, Korea
| | - D-Y Shin
- Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, Korea
| | - S-H Oh
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S-M Jin
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S J Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, Korea
| |
Collapse
|
56
|
Kim TS, Kim JM, Kwon CHD, Kim SJ, Joh JW, Lee SK. Prognostic Factors Predicting Poor Outcome in Living-Donor Liver Transplantation for Fulminant Hepatic Failure. Transplant Proc 2018; 49:1118-1122. [PMID: 28583539 DOI: 10.1016/j.transproceed.2017.03.031] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Living-donor liver transplantation (LDLT) has been accepted as feasible treatment for fulminant hepatic failure (FHF), although it has generated several debatable issues. In this study, we investigated the prognostic factors predicting fatal outcome after LDLT for FHF. METHODS From April 1999 to April 2011, 60 patients underwent LT for acute liver failure, including 42 patients for FHF at Samsung Medical Center, Seoul, Korea. Among 42 patients, 30 patients underwent LDLT for FHF, and the database of these patients was analyzed retrospectively to investigate the prognostic factors after LDLT for FHF. RESULTS Among 30 patients, 7 patients (23%) died during the in-hospital period within 6 months, and 23 patients (77%) survived until recently. In univariate analyses, donor age (>35 years), graft volume (GV)/standard liver volume (SLV) (<50%), cold ischemic time (>120 minutes), hepatic encephalopathy (grade IV), hepato-renal syndrome (HRS), and history of ventilator care were associated with fatal outcome after LDLT for FHF. In multivariate analyses, HRS, GV/SLV (<50%), and donor age (>35 years) were significantly associated with fatal outcome. Although the statistical significance was not shown in this analysis (P = .059), hepatic encephalopathy grade IV also appears to be a risk factor predicting fatal outcome. CONCLUSIONS The survival of patients with FHF undergoing LDLT was comparable to that in published data. In this study, HRS, GV/SLV <50%, and donor age >35 years are the independent poor prognostic factors.
Collapse
Affiliation(s)
- T-S Kim
- Department of Surgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
| | - J M Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - C H D Kwon
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S J Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J-W Joh
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
| | - S-K Lee
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
57
|
Campbell BCV, van Zwam WH, Goyal M, Menon BK, Dippel DWJ, Demchuk AM, Bracard S, White P, Dávalos A, Majoie CBLM, van der Lugt A, Ford GA, de la Ossa NP, Kelly M, Bourcier R, Donnan GA, Roos YBWEM, Bang OY, Nogueira RG, Devlin TG, van den Berg LA, Clarençon F, Burns P, Carpenter J, Berkhemer OA, Yavagal DR, Pereira VM, Ducrocq X, Dixit A, Quesada H, Epstein J, Davis SM, Jansen O, Rubiera M, Urra X, Micard E, Lingsma HF, Naggara O, Brown S, Guillemin F, Muir KW, van Oostenbrugge RJ, Saver JL, Jovin TG, Hill MD, Mitchell PJ, Berkhemer OA, Fransen PSS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJH, van Walderveen MAA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama à Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle J, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach Z, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Wakhloo A, Moonis M, Henninger N, Goddeau R, Massari F, Minaeian A, Lozano JD, Ramzan M, Stout C, Patel A, Majoie CB, Tunguturi A, Onteddu S, Carandang R, Howk M, Ribó M, Sanjuan E, Rubiera M, Pagola J, Flores A, Muchada M, Dippel DW, Meler P, Huerga E, Gelabert S, Coscojuela P, Tomasello A, Rodriguez D, Santamarina E, Maisterra O, Boned S, Seró L, Brown MM, Rovira A, Molina CA, Millán M, Muñoz L, Pérez de la Ossa N, Gomis M, Dorado L, López-Cancio E, Palomeras E, Munuera J, Liebig T, García Bermejo P, Remollo S, Castaño C, García-Sort R, Cuadras P, Puyalto P, Hernández-Pérez M, Jiménez M, Martínez-Piñeiro A, Lucente G, Stijnen T, Dávalos A, Chamorro A, Urra X, Obach V, Cervera A, Amaro S, Llull L, Codas J, Balasa M, Navarro J, Andersson T, Ariño H, Aceituno A, Rudilosso S, Renu A, Macho JM, San Roman L, Blasco J, López A, Macías N, Cardona P, Mattle H, Quesada H, Rubio F, Cano L, Lara B, de Miquel MA, Aja L, Serena J, Cobo E, Albers GW, Lees KR, Wahlgren N, Arenillas J, Roberts R, Minhas P, Al-Ajlan F, Salluzzi M, Zimmel L, Patel S, Eesa M, Martí-Fàbregas J, Jankowitz B, van der Heijden E, Serena J, Salvat-Plana M, López-Cancio E, Bracard S, Ducrocq X, Anxionnat R, Baillot PA, Barbier C, Derelle AL, Lacour JC, Ghannouti N, Richard S, Samson Y, Sourour N, Baronnet-Chauvet F, Clarencon F, Crozier S, Deltour S, Di Maria F, Le Bouc R, Leger A, Fleitour N, Mutlu G, Rosso C, Szatmary Z, Yger M, Zavanone C, Bakchine S, Pierot L, Caucheteux N, Estrade L, Kadziolka K, Hooijenga I, Leautaud A, Renkes C, Serre I, Desal H, Guillon B, Boutoleau-Bretonniere C, Daumas-Duport B, De Gaalon S, Derkinderen P, Evain S, Puppels C, Herisson F, Laplaud DA, Lebouvier T, Lintia-Gaultier A, Pouclet-Courtemanche H, Rouaud T, Rouaud Jaffrenou V, Schunck A, Sevin-Allouet M, Toulgoat F, Pellikaan W, Wiertlewski S, Gauvrit JY, Ronziere T, Cahagne V, Ferre JC, Pinel JF, Raoult H, Mas JL, Meder JF, Al Najjar-Carpentier AA, Geerling A, Birchenall J, Bodiguel E, Calvet D, Domigo V, Godon-Hardy S, Guiraud V, Lamy C, Majhadi L, Morin L, Naggara O, Lindl-Velema A, Trystram D, Turc G, Berge J, Sibon I, Menegon P, Barreau X, Rouanet F, Debruxelles S, Kazadi A, Renou P, van Vemde G, Fleury O, Pasco-Papon A, Dubas F, Caroff J, Godard Ducceschi S, Hamon MA, Lecluse A, Marc G, Giroud M, Ricolfi F, de Ridder A, Bejot Y, Chavent A, Gentil A, Kazemi A, Osseby GV, Voguet C, Mahagne MH, Sedat J, Chau Y, Suissa L, Greebe P, Lachaud S, Houdart E, Stapf C, Buffon Porcher F, Chabriat H, Guedin P, Herve D, Jouvent E, Mawet J, Saint-Maurice JP, de Bont-Stikkelbroeck J, Schneble HM, Turjman F, Nighoghossian N, Berhoune NN, Bouhour F, Cho TH, Derex L, Felix S, Gervais-Bernard H, Gory B, de Meris J, Manera L, Mechtouff L, Ritzenthaler T, Riva R, Salaris Silvio F, Tilikete C, Blanc R, Obadia M, Bartolini MB, Gueguen A, Janssen K, Piotin M, Pistocchi S, Redjem H, Drouineau J, Neau JP, Godeneche G, Lamy M, Marsac E, Velasco S, Clavelou P, Struijk W, Chabert E, Bourgois N, Cornut-Chauvinc C, Ferrier A, Gabrillargues J, Jean B, Marques AR, Vitello N, Detante O, Barbieux M, Licher S, Boubagra K, Favre Wiki I, Garambois K, Tahon F, Ashok V, Voguet C, Coskun O, Guedin P, Rodesch G, Lapergue B, Boodt N, Bourdain F, Evrard S, Graveleau P, Decroix JP, Wang A, Sellal F, Ahle G, Carelli G, Dugay MH, Gaultier C, Ros A, Lebedinsky AP, Lita L, Musacchio RM, Renglewicz-Destuynder C, Tournade A, Vuillemet F, Montoro FM, Mounayer C, Faugeras F, Gimenez L, Venema E, Labach C, Lautrette G, Denier C, Saliou G, Chassin O, Dussaule C, Melki E, Ozanne A, Puccinelli F, Sachet M, Slokkers I, Sarov M, Bonneville JF, Moulin T, Biondi A, De Bustos Medeiros E, Vuillier F, Courtheoux P, Viader F, Apoil-Brissard M, Bataille M, Ganpat RJ, Bonnet AL, Cogez J, Kazemi A, Touze E, Leclerc X, Leys D, Aggour M, Aguettaz P, Bodenant M, Cordonnier C, Mulder M, Deplanque D, Girot M, Henon H, Kalsoum E, Lucas C, Pruvo JP, Zuniga P, Bonafé A, Arquizan C, Costalat V, Saiedie N, Machi P, Mourand I, Riquelme C, Bounolleau P, Arteaga C, Faivre A, Bintner M, Tournebize P, Charlin C, Darcel F, Heshmatollah A, Gauthier-Lasalarie P, Jeremenko M, Mouton S, Zerlauth JB, Lamy C, Hervé D, Hassan H, Gaston A, Barral FG, Garnier P, Schipperen S, Beaujeux R, Wolff V, Herbreteau D, Debiais S, Murray A, Ford G, Muir KW, White P, Brown MM, Clifton A, Vinken S, Freeman J, Ford I, Markus H, Wardlaw J, Lees KR, Molyneux A, Robinson T, Lewis S, Norrie J, Robertson F, van Boxtel T, Perry R, Dixit A, Cloud G, Clifton A, Madigan J, Roffe C, Nayak S, Lobotesis K, Smith C, Herwadkar A, Koets J, Kandasamy N, Goddard T, Bamford J, Subramanian G, Lenthall R, Littleton E, Lamin S, Storey K, Ghatala R, Banaras A, Boers M, Aeron-Thomas J, Hazel B, Maguire H, Veraque E, Harrison L, Keshvara R, Cunningham J, Santos E, Borst J, Jansen I, Kappelhof M, Lucas M, Geuskens R, Barros RS, Dobbe R, Csizmadia M, Hill MD, Goyal M, Demchuk AM, Menon BK, Eesa M, Ryckborst KJ, Wright MR, Kamal NR, Andersen L, Randhawa PA, Stewart T, Patil S, Minhas P, Almekhlafi M, Mishra S, Clement F, Sajobi T, Shuaib A, Montanera WJ, Roy D, Silver FL, Jovin TG, Frei DF, Sapkota B, Rempel JL, Thornton J, Williams D, Tampieri D, Poppe AY, Dowlatshahi D, Wong JH, Mitha AP, Subramaniam S, Hull G, Lowerison MW, Sajobi T, Salluzzi M, Wright MR, Maxwell M, Lacusta S, Drupals E, Armitage K, Barber PA, Smith EE, Morrish WF, Coutts SB, Derdeyn C, Demaerschalk B, Yavagal D, Martin R, Brant R, Yu Y, Willinsky RA, Montanera WJ, Weill A, Kenney C, Aram H, Stewart T, Stys PK, Watson TW, Klein G, Pearson D, Couillard P, Trivedi A, Singh D, Klourfeld E, Imoukhuede O, Nikneshan D, Blayney S, Reddy R, Choi P, Horton M, Musuka T, Dubuc V, Field TS, Desai J, Adatia S, Alseraya A, Nambiar V, van Dijk R, Wong JH, Mitha AP, Morrish WF, Eesa M, Newcommon NJ, Shuaib A, Schwindt B, Butcher KS, Jeerakathil T, Buck B, Khan K, Naik SS, Emery DJ, Owen RJ, Kotylak TB, Ashforth RA, Yeo TA, McNally D, Siddiqui M, Saqqur M, Hussain D, Kalashyan H, Manosalva A, Kate M, Gioia L, Hasan S, Mohammad A, Muratoglu M, Williams D, Thornton J, Cullen A, Brennan P, O'Hare A, Looby S, Hyland D, Duff S, McCusker M, Hallinan B, Lee S, McCormack J, Moore A, O'Connor M, Donegan C, Brewer L, Martin A, Murphy S, O'Rourke K, Smyth S, Kelly P, Lynch T, Daly T, O'Brien P, O'Driscoll A, Martin M, Daly T, Collins R, Coughlan T, McCabe D, Murphy S, O'Neill D, Mulroy M, Lynch O, Walsh T, O'Donnell M, Galvin T, Harbison J, McElwaine P, Mulpeter K, McLoughlin C, Reardon M, Harkin E, Dolan E, Watts M, Cunningham N, Fallon C, Gallagher S, Cotter P, Crowe M, Doyle R, Noone I, Lapierre M, Coté VA, Lanthier S, Odier C, Durocher A, Raymond J, Weill A, Daneault N, Deschaintre Y, Jankowitz B, Baxendell L, Massaro L, Jackson-Graves C, Decesare S, Porter P, Armbruster K, Adams A, Billigan J, Oakley J, Ducruet A, Jadhav A, Giurgiutiu DV, Aghaebrahim A, Reddy V, Hammer M, Starr M, Totoraitis V, Wechsler L, Streib S, Rangaraju S, Campbell D, Rocha M, Gulati D, Silver FL, Krings T, Kalman L, Cayley A, Williams J, Stewart T, Wiegner R, Casaubon LK, Jaigobin C, del Campo JM, Elamin E, Schaafsma JD, Willinsky RA, Agid R, Farb R, ter Brugge K, Sapkoda BL, Baxter BW, Barton K, Knox A, Porter A, Sirelkhatim A, Devlin T, Dellinger C, Pitiyanuvath N, Patterson J, Nichols J, Quarfordt S, Calvert J, Hawk H, Fanale C, Frei DF, Bitner A, Novak A, Huddle D, Bellon R, Loy D, Wagner J, Chang I, Lampe E, Spencer B, Pratt R, Bartt R, Shine S, Dooley G, Nguyen T, Whaley M, McCarthy K, Teitelbaum J, Tampieri D, Poon W, Campbell N, Cortes M, Dowlatshahi D, Lum C, Shamloul R, Robert S, Stotts G, Shamy M, Steffenhagen N, Blacquiere D, Hogan M, AlHazzaa M, Basir G, Lesiuk H, Iancu D, Santos M, Choe H, Weisman DC, Jonczak K, Blue-Schaller A, Shah Q, MacKenzie L, Klein B, Kulandaivel K, Kozak O, Gzesh DJ, Harris LJ, Khoury JS, Mandzia J, Pelz D, Crann S, Fleming L, Hesser K, Beauchamp B, Amato-Marzialli B, Boulton M, Lopez- Ojeda P, Sharma M, Lownie S, Chan R, Swartz R, Howard P, Golob D, Gladstone D, Boyle K, Boulos M, Hopyan J, Yang V, Da Costa L, Holmstedt CA, Turk AS, Navarro R, Jauch E, Ozark S, Turner R, Phillips S, Shankar J, Jarrett J, Gubitz G, Maloney W, Vandorpe R, Schmidt M, Heidenreich J, Hunter G, Kelly M, Whelan R, Peeling L, Burns PA, Hunter A, Wiggam I, Kerr E, Watt M, Fulton A, Gordon P, Rennie I, Flynn P, Smyth G, O'Leary S, Gentile N, Linares G, McNelis P, Erkmen K, Katz P, Azizi A, Weaver M, Jungreis C, Faro S, Shah P, Reimer H, Kalugdan V, Saposnik G, Bharatha A, Li Y, Kostyrko P, Santos M, Marotta T, Montanera W, Sarma D, Selchen D, Spears J, Heo JH, Jeong K, Kim DJ, Kim BM, Kim YD, Song D, Lee KJ, Yoo J, Bang OY, Rho S, Lee J, Jeon P, Kim KH, Cha J, Kim SJ, Ryoo S, Lee MJ, Sohn SI, Kim CH, Ryu HG, Hong JH, Chang HW, Lee CY, Rha J, Davis SM, Donnan GA, Campbell BCV, Mitchell PJ, Churilov L, Yan B, Dowling R, Yassi N, Oxley TJ, Wu TY, Silver G, McDonald A, McCoy R, Kleinig TJ, Scroop R, Dewey HM, Simpson M, Brooks M, Coulton B, Krause M, Harrington TJ, Steinfort B, Faulder K, Priglinger M, Day S, Phan T, Chong W, Holt M, Chandra RV, Ma H, Young D, Wong K, Wijeratne T, Tu H, Mackay E, Celestino S, Bladin CF, Loh PS, Gilligan A, Ross Z, Coote S, Frost T, Parsons MW, Miteff F, Levi CR, Ang T, Spratt N, Kaauwai L, Badve M, Rice H, de Villiers L, Barber PA, McGuinness B, Hope A, Moriarty M, Bennett P, Wong A, Coulthard A, Lee A, Jannes J, Field D, Sharma G, Salinas S, Cowley E, Snow B, Kolbe J, Stark R, King J, Macdonnell R, Attia J, D'Este C, Saver JL, Goyal M, Diener HC, Levy EI, Bonafé A, Mendes Pereira V, Jahan R, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, von Kummer R, Smith W, Turjman F, Hamilton S, Chiacchierini R, Amar A, Sanossian N, Loh Y, Devlin T, Baxter B, Hawk H, Sapkota B, Quarfordt S, Sirelkhatim A, Dellinger C, Barton K, Reddy VK, Ducruet A, Jadhav A, Horev A, Giurgiutiu DV, Totoraitis V, Hammer M, Jankowitz B, Wechsler L, Rocha M, Gulati D, Campbell D, Star M, Baxendell L, Oakley J, Siddiqui A, Hopkins LN, Snyder K, Sawyer R, Hall S, Costalat V, Riquelme C, Machi P, Omer E, Arquizan C, Mourand I, Charif M, Ayrignac X, Menjot de Champfleur N, Leboucq N, Gascou G, Moynier M, du Mesnil de Rochemont R, Singer O, Berkefeld J, Foerch C, Lorenz M, Pfeilschifer W, Hattingen E, Wagner M, You SJ, Lescher S, Braun H, Dehkharghani S, Belagaje SR, Anderson A, Lima A, Obideen M, Haussen D, Dharia R, Frankel M, Patel V, Owada K, Saad A, Amerson L, Horn C, Doppelheuer S, Schindler K, Lopes DK, Chen M, Moftakhar R, Anton C, Smreczak M, Carpenter JS, Boo S, Rai A, Roberts T, Tarabishy A, Gutmann L, Brooks C, Brick J, Domico J, Reimann G, Hinrichs K, Becker M, Heiss E, Selle C, Witteler A, Al-Boutros S, Danch MJ, Ranft A, Rohde S, Burg K, Weimar C, Zegarac V, Hartmann C, Schlamann M, Göricke S, Ringlestein A, Wanke I, Mönninghoff C, Dietzold M, Budzik R, Davis T, Eubank G, Hicks WJ, Pema P, Vora N, Mejilla J, Taylor M, Clark W, Rontal A, Fields J, Peterson B, Nesbit G, Lutsep H, Bozorgchami H, Priest R, Ologuntoye O, Barnwell S, Dogan A, Herrick K, Takahasi C, Beadell N, Brown B, Jamieson S, Hussain MS, Russman A, Hui F, Wisco D, Uchino K, Khawaja Z, Katzan I, Toth G, Cheng-Ching E, Bain M, Man S, Farrag A, George P, John S, Shankar L, Drofa A, Dahlgren R, Bauer A, Itreat A, Taqui A, Cerejo R, Richmond A, Ringleb P, Bendszus M, Möhlenbruch M, Reiff T, Amiri H, Purrucker J, Herweh C, Pham M, Menn O, Ludwig I, Acosta I, Villar C, Morgan W, Sombutmai C, Hellinger F, Allen E, Bellew M, Gandhi R, Bonwit E, Aly J, Ecker RD, Seder D, Morris J, Skaletsky M, Belden J, Baker C, Connolly LS, Papanagiotou P, Roth C, Kastrup A, Politi M, Brunner F, Alexandrou M, Merdivan H, Ramsey C, Given II C, Renfrow S, Deshmukh V, Sasadeusz K, Vincent F, Thiesing JT, Putnam J, Bhatt A, Kansara A, Caceves D, Lowenkopf T, Yanase L, Zurasky J, Dancer S, Freeman B, Scheibe-Mirek T, Robison J, Rontal A, Roll J, Clark D, Rodriguez M, Fitzsimmons BFM, Zaidat O, Lynch JR, Lazzaro M, Larson T, Padmore L, Das E, Farrow-Schmidt A, Hassan A, Tekle W, Cate C, Jansen O, Cnyrim C, Wodarg F, Wiese C, Binder A, Riedel C, Rohr A, Lang N, Laufs H, Krieter S, Remonda L, Diepers M, Añon J, Nedeltchev K, Kahles T, Biethahn S, Lindner M, Chang V, Gächter C, Esperon C, Guglielmetti M, Arenillas Lara JF, Martínez Galdámez M, Calleja Sanz AI, Cortijo Garcia E, Garcia Bermejo P, Perez S, Mulero Carrillo P, Crespo Vallejo E, Ruiz Piñero M, Lopez Mesonero L, Reyes Muñoz FJ, Brekenfeld C, Buhk JH, Krützelmann A, Thomalla G, Cheng B, Beck C, Hoppe J, Goebell E, Holst B, Grzyska U, Wortmann G, Starkman S, Duckwiler G, Jahan R, Rao N, Sheth S, Ng K, Noorian A, Szeder V, Nour M, McManus M, Huang J, Tarpley J, Tateshima S, Gonzalez N, Ali L, Liebeskind D, Hinman J, Calderon-Arnulphi M, Liang C, Guzy J, Koch S, DeSousa K, Gordon-Perue G, Haussen D, Elhammady M, Peterson E, Pandey V, Dharmadhikari S, Khandelwal P, Malik A, Pafford R, Gonzalez P, Ramdas K, Andersen G, Damgaard D, Von Weitzel-Mudersbach P, Simonsen C, Ruiz de Morales Ayudarte N, Poulsen M, Sørensen L, Karabegovich S, Hjørringgaard M, Hjort N, Harbo T, Sørensen K, Deshaies E, Padalino D, Swarnkar A, Latorre JG, Elnour E, El-Zammar Z, Villwock M, Farid H, Balgude A, Cross L, Hansen K, Holtmannspötter M, Kondziella D, Hoejgaard J, Taudorf S, Soendergaard H, Wagner A, Cronquist M, Stavngaard T, Cortsen M, Krarup LH, Hyldal T, Haring HP, Guggenberger S, Hamberger M, Trenkler J, Sonnberger M, Nussbaumer K, Dominger C, Bach E, Jagadeesan BD, Taylor R, Kim J, Shea K, Tummala R, Zacharatos H, Sandhu D, Ezzeddine M, Grande A, Hildebrandt D, Miller K, Scherber J, Hendrickson A, Jumaa M, Zaidi S, Hendrickson T, Snyder V, Killer-Oberpfalzer M, Mutzenbach J, Weymayr F, Broussalis E, Stadler K, Jedlitschka A, Malek A, Mueller-Kronast N, Beck P, Martin C, Summers D, Day J, Bettinger I, Holloway W, Olds K, Arkin S, Akhtar N, Boutwell C, Crandall S, Schwartzman M, Weinstein C, Brion B, Prothmann S, Kleine J, Kreiser K, Boeckh-Behrens T, Poppert H, Wunderlich S, Koch ML, Biberacher V, Huberle A, Gora-Stahlberg G, Knier B, Meindl T, Utpadel-Fischler D, Zech M, Kowarik M, Seifert C, Schwaiger B, Puri A, Hou S. Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data. Lancet Neurol 2018; 17:47-53. [DOI: 10.1016/s1474-4422(17)30407-6] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 10/05/2017] [Accepted: 10/11/2017] [Indexed: 10/18/2022]
|
58
|
Kwon HJ, Kim DH, Jang HR, Jung SH, Han DH, Sung HH, Park JB, Lee JE, Huh W, Kim SJ, Kim YG, Kim DJ, Oh HY. Predictive Factors of Renal Adaptation After Nephrectomy in Kidney Donors. Transplant Proc 2017; 49:1999-2006. [PMID: 29149951 DOI: 10.1016/j.transproceed.2017.09.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Revised: 08/01/2017] [Accepted: 09/02/2017] [Indexed: 11/16/2022]
Abstract
BACKGROUND Despite compensatory hyperfiltration in remaining nephrons following donor nephrectomy, some donors show impaired renal adaptation and low estimated glomerular filtration rate (eGFR). We investigated the factors predicting early renal adaptation after nephrectomy and identified kidney donors at risk of inadequate renal adaptation. METHODS A total of 265 living kidney donors from 2010 to 2013 were retrospectively analyzed. Renal function was serially followed for 6 months after the operation. Regression analyses were performed to identify the independent predictors of low eGFR (eGFR <60 mL/min/1.73 m2) and impaired renal adaptation (%Modification of Diet in Renal Disease [MDRD] <66% of baseline eGFR). RESULTS A total of 148 donors belonged to the low eGFR group, and changes in eGFR (ΔeGFR) at postoperative (PO) 1 day and 1 month were identified as independent predictors of low eGFR. Impaired renal adaptation was related to age, ΔeGFR PO 2-3 days, and ΔeGFR PO 1 month. Early renal adaptation was associated with age, male gender, and residual kidney computerized tomography angiography (CTA) volume. The best sensitivity and specificity were obtained with a cutoff value of ΔeGFR 31 at PO 1 day and 1 month for predicting low eGFR and with a value of ΔeGFR 27 at PO 2-3 days and 1 month for predicting impaired renal adaptation. CONCLUSIONS Our study showed that the degree of early renal adaptation determines subsequent renal function in kidney donors. Closer monitoring and management may be required in old or male donors with small residual CTA kidney volume as well as donors with persistent ΔeGFR >27 within 1 month of nephrectomy.
Collapse
Affiliation(s)
- H J Kwon
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - D H Kim
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H R Jang
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
| | - S-H Jung
- Biostatics and Clinical Epidemiology Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - D H Han
- Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H H Sung
- Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J B Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J E Lee
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - W Huh
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S J Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y-G Kim
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - D J Kim
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H Y Oh
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
59
|
Park J, Park SW, Cho SI, Park I, Kim YH, Park EY, Oh JK, Kim SJ, Park JH, Lim MK. Planning of national prospective study on tobacco behavior transition among adolescents in Korea. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx186.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- J Park
- Graduate School of Cancer Science and Policy, National Cancer Center, Daegu, South Korea
| | - SW Park
- Catholic University of Daegu, School of Medicine, Daegym, South Korea
| | - SI Cho
- Seoul National University, Seoul, South Korea
| | - I Park
- Pukyong National University, Busan, South Korea
| | - YH Kim
- Pukyong National University, Busan, South Korea
| | - EY Park
- National Cancer Center, Goyang, South Korea
| | - JK Oh
- Graduate School of Cancer Science and Policy, National Cancer Center, Daegu, South Korea
| | - SJ Kim
- National Cancer Center, Goyang, South Korea
| | - JH Park
- National Cancer Center, Goyang, South Korea
| | - MK Lim
- Graduate School of Cancer Science and Policy, National Cancer Center, Daegu, South Korea
| |
Collapse
|
60
|
Acuna SA, Sutradhar R, Camacho X, Daly C, Del Giudice ME, Kim SJ, Baxter NN. Uptake of Cancer Screening Tests Among Recipients of Solid Organ Transplantation. Am J Transplant 2017; 17:2434-2443. [PMID: 28485086 DOI: 10.1111/ajt.14272] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2016] [Revised: 02/23/2017] [Accepted: 03/01/2017] [Indexed: 01/25/2023]
Abstract
Population-based cancer screening recommendations are also suggested for solid organ transplant recipients (SOTR); however, recommendation adherence is unknown. In a population-based cohort of SOTR in Ontario between 1997 and 2010, we determined the uptake of breast, cervical, and colorectal cancer screening tests and identified factors associated with up-to-date screening using recurrent event analysis. We identified 4436 SOTR eligible for colorectal, 2252 for cervical, and 1551 for breast cancer screening. Of those, 3437 (77.5%), 1572 (69.8%), and 1417 (91.4%), respectively, were not up-to-date for cancer screening tests during the observation period. However, these rates are likely an overestimate due to the inability to differentiate between tests done for screening or for diagnosis. SOTR with fewer comorbidities had higher rates of becoming screen up-to-date. Assessment by a primary care provider (PCP) was associated with becoming up-to-date with cancer screening (breast relative risk [RR] = 1.40, 95% confidence interval [CI]: 1.12-1.76, cervical RR = 1.29, 95% CI: 1.06-1.57, colorectal RR = 1.30, 95% CI: 1.15-1.48). Similar results were observed for continuity of care by transplant specialist at a transplant center. In conclusion, cancer screening for most SOTR does not adhere to standard recommendations. Involvement of PCPs in posttransplant care and continuity of care at a transplant center may improve the uptake of screening.
Collapse
Affiliation(s)
- S A Acuna
- Department of Surgery, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.,Institute of Health, Policy Management, and Evaluation, University of Toronto, Toronto, Canada
| | - R Sutradhar
- Institute of Health, Policy Management, and Evaluation, University of Toronto, Toronto, Canada.,Institute for Clinical Evaluative Sciences, Toronto, Ontario
| | - X Camacho
- Institute for Clinical Evaluative Sciences, Toronto, Ontario
| | - C Daly
- Department of Surgery, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
| | - M E Del Giudice
- Sunnybrook Academic Family Health Team, Department of Family and Community Medicine, University of Toronto, Toronto, Canada
| | - S J Kim
- Institute of Health, Policy Management, and Evaluation, University of Toronto, Toronto, Canada.,Institute for Clinical Evaluative Sciences, Toronto, Ontario.,Division of Nephrology, University Health Network, Toronto, Canada
| | - N N Baxter
- Department of Surgery, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.,Institute of Health, Policy Management, and Evaluation, University of Toronto, Toronto, Canada.,Institute for Clinical Evaluative Sciences, Toronto, Ontario.,Department of Surgery, University of Toronto, Toronto, Canada
| |
Collapse
|
61
|
Maravilla KR, San-Juan D, Kim SJ, Elizondo-Riojas G, Fink JR, Escobar W, Bag A, Roberts DR, Hao J, Pitrou C, Tsiouris AJ, Herskovits E, Fiebach JB. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study). AJNR Am J Neuroradiol 2017; 38:1681-1688. [PMID: 28663267 DOI: 10.3174/ajnr.a5316] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 06/06/2017] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Effective management of patients with brain tumors depends on accurate detection and characterization of lesions. This study aimed to demonstrate the noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors. MATERIALS AND METHODS This multicenter, double-blind, randomized, controlled intraindividual, crossover, noninferiority study included 279 patients. Both contrast agents (dose = 0.1 mmol/kg of body weight) were assessed with 2 identical MRIs at a time interval of 2-14 days. The primary end point was overall lesion visualization and characterization, scored independently by 3 off-site readers on a 4-point scale, ranging from "poor" to "excellent." Secondary end points were qualitative assessments (lesion border delineation, internal morphology, degree of contrast enhancement, diagnostic confidence), quantitative measurements (signal intensity), and safety (adverse events). All qualitative assessments were also performed on-site. RESULTS For all 3 readers, images of most patients (>90%) were scored good or excellent for overall lesion visualization and characterization with either contrast agent; and the noninferiority of gadoterate meglumine versus gadobutrol was statistically demonstrated. No significant differences were observed between the 2 contrast agents regarding qualitative end points despite quantitative mean lesion percentage enhancement being higher with gadobutrol (P < .001). Diagnostic confidence was high/excellent for all readers in >81% of the patients with both contrast agents. Similar percentages of patients with adverse events related to the contrast agents were observed with gadoterate meglumine (7.8%) and gadobutrol (7.3%), mainly injection site pain. CONCLUSIONS The noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors was demonstrated.
Collapse
Affiliation(s)
- K R Maravilla
- From the Department of Radiology (K.R.M., J.R.F.), University of Washington Medical Center, Seattle, Washington
| | - D San-Juan
- Clinical Research Department (D.S.-J.), National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - S J Kim
- Department of Radiology (S.J.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - G Elizondo-Riojas
- Universidad Autonoma de Nuevo Leon (G.E.-R.), Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Mexico
| | - J R Fink
- From the Department of Radiology (K.R.M., J.R.F.), University of Washington Medical Center, Seattle, Washington
| | - W Escobar
- Centro Medico Imbanaco (W.E.), Cali, Colombia
| | - A Bag
- Department of Radiology (A.B.), University of Alabama, Birmingham, Alabama
| | - D R Roberts
- Medical University of South Carolina (D.R.R.), Charleston, South Carolina
| | - J Hao
- Guerbet (J.H., C.P.), Roissy-Charles de Gaulle, France
| | - C Pitrou
- Guerbet (J.H., C.P.), Roissy-Charles de Gaulle, France
| | - A J Tsiouris
- Department of Radiology (A.J.T.), Weill Cornell Medical College, New York, New York
| | - E Herskovits
- Department of Radiology (E.H.), University of Maryland, Baltimore, Maryland
| | - J B Fiebach
- Center for Stroke Research Berlin (J.B.F.), Charité-Universitätsmedizin, Berlin, Germany
| |
Collapse
|
62
|
Abstract
Acute oral toxicity of methanol extract of Asiasari radix was evaluated in ICR mice of both sexes. In this study, mice were administrated orally with dosages of 1000, 3000, and 5000 mg/kg body weight of Asiasari radix extract. Mortality, signs of toxicity, body weight, food consumption, and gross findings were observed for 14 days post treatment of Asiasari radix extract. No mortality, signs of toxicity, and abnormalities in gross findings were observed. In addition, no significant differences were noticed in the body and organ weights between the control and treated groups of both sexes. These results show that the methanol extract of Asiasari radix is toxicologically safe by oral administration.
Collapse
Affiliation(s)
- T Ramesh
- Department of Pharmacology, School of Dentistry, Kyung Hee University, Seoul, South Korea
| | | | | | | |
Collapse
|
63
|
Lee KW, Choi B, Kim YM, Cho CW, Park H, Moon JI, Choi GS, Park JB, Kim SJ. Major Histocompatibilty Complex-Restricted Adaptive Immune Responses to CT26 Colon Cancer Cell Line in Mixed Allogeneic Chimera. Transplant Proc 2017; 49:1153-1159. [PMID: 28583547 DOI: 10.1016/j.transproceed.2017.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
BACKGROUND Although the induction of mixed allogeneic chimera shows promising clinical tolerance results in organ transplantation, its clinical relevance as an anti-cancer therapy is yet unknown. We introduced a mixed allogenic chimera setting with the use of a murine colon cancer cell line, CT26, by performing double bone marrow transplantation. METHODS We analyzed donor- and recipient-restricted anti-cancer T-cell responses, and phenotypes of subpopulations of T cells. The protocol involves challenging 1 × 105 cells of CT26 cells intra-hepatically on day 50 after bone marrow transplantation, and, by use of CT26 lysates and an H-2Ld-restricted AH1 pentamer, flow cytometric analysis was performed to detect the generation of cancer-specific CD4+ and CD8+ T cells at various time points. RESULTS We found that immunocompetence against tumors depends heavily on cancer-specific CD8+ T-cell responses in a major histocompatibility complex-restricted manner; the evidence was further supported by the increase of interferon-γ-secreting CD4+ T cells. Moreover, we demonstrated that during the effector immune response to CT26 cancer challenge, there was a presence of central memory cells (CD62LhiCCR7+) as well as effector memory cells (CD62LloCCR7-). Moreover, mixed allogeneic chimeras (BALB/c to C56BL/6 or vice versa) showed similar or heightened immune responses to CT26 cells compared with that of wild-type mice. CONCLUSIONS Our results suggest that the responses of primary immunocompetency and of pre-existing memory T cells against allogeneic cancer are sustained and preserved long-term in a mixed allogeneic chimeric environment.
Collapse
Affiliation(s)
- K W Lee
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Transplantation Research Center, Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - B Choi
- Transplantation Research Center, Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y M Kim
- Laboratory of Immunology and Infectious Disease, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea
| | - C W Cho
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Transplantation Research Center, Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Transplantation Research Center, Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J I Moon
- Department of Surgery, Konyang University Hospital, Daejeon, Korea
| | - G-S Choi
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
| | - J B Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Transplantation Research Center, Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S J Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Transplantation Research Center, Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
64
|
Naylor KL, Dixon SN, Garg AX, Kim SJ, Blake PG, Nesrallah GE, McCallum MK, D'Antonio C, Li AH, Knoll GA. Variation in Access to Kidney Transplantation Across Renal Programs in Ontario, Canada. Am J Transplant 2017; 17:1585-1593. [PMID: 28068455 DOI: 10.1111/ajt.14133] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Revised: 11/10/2016] [Accepted: 11/12/2016] [Indexed: 01/25/2023]
Abstract
In the United States, kidney transplant rates vary significantly across end-stage renal disease (ESRD) networks. We conducted a population-based cohort study to determine whether there was variability in kidney transplant rates across renal programs in a health care system distinct from the United States. We included incident chronic dialysis patients in Ontario, Canada, from 2003 to 2013 and determined the 1-, 5-, and 10-year cumulative incidence of kidney transplantation in 27 regional renal programs (similar to U.S. ESRD networks). We also assessed the cumulative incidence of kidney transplant for "healthy" dialysis patients (aged 18-50 years without diabetes, coronary disease, or malignancy). We calculated standardized transplant ratios (STRs) using a Cox proportional hazards model, adjusting for patient characteristics (maximum possible follow-up of 11 years). Among 23 022 chronic dialysis patients, the 10-year cumulative incidence of kidney transplantation ranged from 7.4% (95% confidence interval [CI] 4.8-10.7%) to 31.4% (95% CI 16.5-47.5%) across renal programs. Similar variability was observed in our healthy cohort. STRs ranged from 0.3 (95% CI 0.2-0.5) to 1.5 (95% CI 1.4-1.7) across renal programs. There was significant variation in kidney transplant rates across Ontario renal programs despite patients having access to the same publicly funded health care system.
Collapse
Affiliation(s)
- K L Naylor
- Institute for Clinical Evaluative Sciences (ICES), London, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - S N Dixon
- Institute for Clinical Evaluative Sciences (ICES), London, Ontario, Canada.,Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada
| | - A X Garg
- Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada.,Division of Nephrology, Western University, London, Ontario, Canada
| | - S J Kim
- Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - P G Blake
- Division of Nephrology, Western University, London, Ontario, Canada
| | - G E Nesrallah
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,Nephrology Program, Humber River Hospital, Toronto, Ontario, Canada
| | - M K McCallum
- Institute for Clinical Evaluative Sciences (ICES), London, Ontario, Canada
| | - C D'Antonio
- Ontario Renal Network, Toronto, Ontario, Canada
| | - A H Li
- Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada.,Division of Nephrology, Western University, London, Ontario, Canada
| | - G A Knoll
- Division of Nephrology, Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
65
|
Abstract
The mode of action for desleucyl-oritavancin was investigated by adding an antibiotic to Staphylococcus aureus during its growth in a defined medium containing l,d-[1-15N]Ala and l-[1-13C]Lys, or d-[1-15N]Ala. 13C{15N} and 15N{13C} rotational-echo double resonance NMR determined that desleucyl-oritavancin inhibited the incorporation of d-[1-15N]Ala into wall teichoic acid.
Collapse
Affiliation(s)
- J Chang
- Department of Chemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798, USA.
| | | | | |
Collapse
|
66
|
Kim SJ, Lee SH, Lee JH. 0299 TWENTY-FOUR HOUR LIGHT EXPOSURE PATTERN AND SLEEP CONSOLIDATION IN INSOMNIA PATIENTS. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
67
|
Chang YH, Shin YA, Kim JH, Kim HM, Lee DW, Chung HK, Kim SJ, Kim CD, Lee JH, Seo YJ, Im M, Lee Y. Use of whole-exome sequencing to determine the genetic basis of signs of skin youthfulness in Korean women. J Eur Acad Dermatol Venereol 2017; 31:e138-e141. [PMID: 27510323 DOI: 10.1111/jdv.13904] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Y H Chang
- LG Household and Healthcare, Daejeon, Korea
| | - Y A Shin
- Theragen-Etex Bio Institute, Advanced Institute of Convergence Technology, Suwon, Korea
| | - J H Kim
- Theragen-Etex Bio Institute, Advanced Institute of Convergence Technology, Suwon, Korea
| | - H M Kim
- Theragen-Etex Bio Institute, Advanced Institute of Convergence Technology, Suwon, Korea
| | - D W Lee
- Theragen-Etex Bio Institute, Advanced Institute of Convergence Technology, Suwon, Korea
| | - H K Chung
- Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea
| | - S J Kim
- Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea
| | - C D Kim
- Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea
| | - J H Lee
- Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea
| | - Y J Seo
- Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea
| | - M Im
- Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea
| | - Y Lee
- Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea
| |
Collapse
|
68
|
Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Kohno N. Abstract P5-16-10: Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND and AIM:
Findings from a randomized phase 2 JONIE1 trial in women with HER2-negative early breast cancer have shown that the addition of zoledronic acid (ZOL) to neoadjuvant chemotherapy (CT) has potential anticancer benefits in postmenopausal and triple-negative breast cancer patients. We report the data for the prespecified secondary endpoint of disease-free survival (DFS).
METHODS:
We enrolled women with HER2-negative early breast cancer and randomly assigned them to receive CT or CT+ZOL (CTZ). All patients received 4 cycles of FEC100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2), followed by 12 cycles of paclitaxel at 80 mg/m2 weekly. ZOL (4 mg) was administered 3-4 times weekly for 7 weeks to the CTZ group patients. Definitive surgery was performed 3-4 weeks after the last paclitaxel dose. The primary endpoint was pathological complete response (pCR). The secondary endpoints were the clinical response rates, rate of breast-conserving surgery, safety, and DFS (defined as the time from randomization to disease occurrence or death). The trial is registered as UMIN000003261 (www.umin.ac.jp/english/) with ongoing follow-up.
FINDINGS:
Of the 188 patients enrolled, 95 were assigned to the CT group and 93 to the CTZ group. The mean (95% CI) DFS time of the CT group was 5.15 years (4.83-5.47) and that of the CTZ group was 5.38 years (5.11-5.66). The 3-year DFS rate was 84.6% (95% CI 77.2-92.0) in the CT group and 90.7% (84.6-96.8) in the CTZ group with no significant difference (p = 0.120). The particular benefit from ZOL for the neoadjuvant CT seen as improvement of the pCR rate was indicated in the 3-year DFS period for triple-negative cancer cases (CT vs CTZ: 70.6% vs 94.1%), but not for postmenopausal cases.
CONCLUSIONS:
ZOL slightly improved DFS when combined with CT. Although a significant difference was not found in this study, plans are underway for conducting a combined analysis of 3 neoadjuvant CT trials together with ZOL. The improvement of the pCR rate may be associated with DFS in triple-negative cases. Previous studies have shown that ZOL was more efficacious in an estrogen-suppressed condition. However, the short-term application of ZOL in this study may not be sufficient to improve the outcome in postmenopausal patients.
Citation Format: Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Kohno N. Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-10.
Collapse
Affiliation(s)
- T Ishikawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - K Akazawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - Y Hasegawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - H Tanino
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - J Horiguchi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - D Miura
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Hayashi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - S Takao
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - SJ Kim
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - K Yamagami
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Miyashita
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Konishi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - Y Shigeoka
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Suzuki
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - T Taguchi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - T Kubota
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - N Kohno
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| |
Collapse
|
69
|
Kim TY, Kim SJ, Chung HG, Choi JH, Kim SH, Kang JI. Epigenetic alterations of the BDNF gene in combat-related post-traumatic stress disorder. Acta Psychiatr Scand 2017; 135:170-179. [PMID: 27886370 DOI: 10.1111/acps.12675] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/07/2016] [Indexed: 01/28/2023]
Abstract
OBJECTIVE Brain-derived neurotrophic factor (BDNF) plays a crucial role in modulating resilience and vulnerability to stress. The aim of this study was to investigate whether epigenetic regulation of the BDNF gene is a biomarker of post-traumatic stress disorder (PTSD) development among veterans exposed to combat in the Vietnam War. METHODS Using the Clinician-Administered PTSD Scale, combat veterans were grouped into those with (n = 126) and without (n = 122) PTSD. DNA methylation levels at four CpG sites within the BDNF promoter I region were quantified in the peripheral blood using pyrosequencing. The effects of BDNF DNA methylation levels and clinical variables on the diagnosis of PTSD were tested using binary logistic regression analysis. RESULTS Subjects with PTSD showed a higher DNA methylation of four CpG sites at the BDNF promoter compared with those without PTSD. High methylation levels at the BDNF promoter CpG site, high combat exposure, and alcohol problems were significantly associated with PTSD diagnosis. CONCLUSIONS This study demonstrated an association between higher DNA methylation of the BDNF promoter and PTSD diagnosis in combat-exposed individuals. Our findings suggest that altered BDNF methylation may be a valuable biomarker of PTSD after trauma exposure.
Collapse
Affiliation(s)
- T Y Kim
- Department of Neuropsychiatry, Veterans Health Service Medical Center, Seoul, South Korea
| | - S J Kim
- Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, South Korea
| | - H G Chung
- Department of Neuropsychiatry, Veterans Health Service Medical Center, Seoul, South Korea
| | - J H Choi
- Department of Neuropsychiatry, Veterans Health Service Medical Center, Seoul, South Korea
| | - S H Kim
- Department of Psychiatry and Institute of Clinical Psychopharmacology, Dongguk University Ilsan Hospital, Goyang, Gyeonggi, South Korea
| | - J I Kang
- Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, South Korea
| |
Collapse
|
70
|
Lim HJ, Koo TY, Lee J, Huh KH, Park JB, Cho J, Lee S, Ro H, Han S, Park B, Park S, Chung W, Park SK, Kim C, Kim SJ, Kim YS, Ahn C, Yang J. Health-Related Quality of Life of Kidney Transplantation Patients: Results from the KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT) Study. Transplant Proc 2017; 48:844-7. [PMID: 27234749 DOI: 10.1016/j.transproceed.2015.12.101] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Accepted: 12/30/2015] [Indexed: 11/17/2022]
Abstract
BACKGROUND As patient and graft survival rates have been improving after kidney transplantation, health-related quality of life (HR-QOL) has become an important indicator of effective treatment. This study aimed to evaluate changes in HR-QOL after kidney transplantation. MATERIALS AND METHODS The KoreaN cohort study for Outcome in patients With Kidney Transplantation (KNOW-KT) is a multicenter, observational, 9-year, cohort study. The HR-QOL of patients in the KNOW-KT study was assessed before transplantation and 2 years after transplantation using the Kidney Disease Quality of Life Short Form (KDQOL-SF) including chronic kidney disease targeted area and the Medical Outcome Study 36-item Short Form Health Survey (SF-36). Multivariate linear regression was used to identify significant factors associated with follow-up QOL scores. RESULTS A total of 175 patients from 8 centers were analyzed. All QOL scores including the total QOL score, chronic kidney disease targeted score, and SF-36 at the 2-year follow-up were significantly increased compared to baseline values. Both physical and mental scale scores were improved after transplantation. CONCLUSION The QOL scores for both the mental and physical scales were improved at 2 years after kidney transplantation. High glomerular filtration rate at 2 years, high baseline QOL score, and low body mass index were associated with good follow-up QOL scores. Kidney transplantation for an Asian population with end-stage renal disease can result in better QOL as well as better patient and graft survival.
Collapse
Affiliation(s)
- H J Lim
- Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea
| | - T Y Koo
- Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea
| | - J Lee
- Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea
| | - K H Huh
- Department of Transplantation Surgery, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
| | - J B Park
- Department of Surgery, Sungkyunkwan University, Seoul Samsung Medical Center, Seoul, Republic of Korea
| | - J Cho
- Department of Internal Medicine, Kyungpook National University Hospital, Seoul, Republic of Korea
| | - S Lee
- Department of Internal Medicine, Chonbuk National University Hospital, Seoul, Republic of Korea
| | - H Ro
- Department of Internal Medicine, Gachon University, Gil Hospital, Seoul, Republic of Korea
| | - S Han
- Department of Internal Medicine, Keimyung University, Dongsan Medical Center, Seoul, Republic of Korea
| | - B Park
- Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S Park
- Department of Internal Medicine, Keimyung University, Dongsan Medical Center, Seoul, Republic of Korea
| | - W Chung
- Department of Internal Medicine, Gachon University, Gil Hospital, Seoul, Republic of Korea
| | - S K Park
- Department of Internal Medicine, Chonbuk National University Hospital, Seoul, Republic of Korea
| | - C Kim
- Department of Internal Medicine, Kyungpook National University Hospital, Seoul, Republic of Korea
| | - S J Kim
- Department of Surgery, Sungkyunkwan University, Seoul Samsung Medical Center, Seoul, Republic of Korea
| | - Y S Kim
- Department of Transplantation Surgery, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
| | - C Ahn
- Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - J Yang
- Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea.
| |
Collapse
|
71
|
Lee KW, Park JB, Oh DK, Na BG, Choi JY, Cho WT, Lee SH, Park HJ, Cho D, Huh WS, Kim SJ. Short-Term Outcomes of ABO-Incompatible Living Donor Kidney Transplantation With Uniform Protocol: Significance of Baseline Anti-ABO Titer. Transplant Proc 2017; 48:820-6. [PMID: 27234744 DOI: 10.1016/j.transproceed.2016.01.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Accepted: 01/21/2016] [Indexed: 02/06/2023]
Abstract
Antibody-mediated rejection (AMR) is one of the major causes of poor outcomes in ABO-incompatible kidney transplantation (ABOi KT). Studies investigating AMR risk factors found that anti-ABO titer is a major issue. However, the significance of antibody titer has been debated. This retrospective study analyzed AMR risk factors in 59 patients who underwent ABOi KT between August 2010 and January 2015. We also analyzed AMR risk factors in recipients with high anti-ABO baseline titers (≥1:64 on dithiothreitol at 37°C phase or ≥1:256 on antihuman globulin phase). The 2-year patient survival rate was 95.8%, and the 2-year graft survival rate was 94.9%. Nine patients (15.3%) experienced clinical (6 of 59 [10.2%]) or subclinical (3 of 59 [5.1%]) AMR. One patient experienced graft loss from hyperacute rejection. AMR risk factor analysis revealed that baseline antibody titer was associated with incidence of AMR. In patients with high baseline titers, low doses of rituximab (200-mg single-dose), an antibody against CD20, was predictive for AMR. Six patients who received pretransplant intravenous immunoglobulin did not experience AMR even when they had high baseline antibody titers. Our results indicate that a high baseline antibody titer affected the incidence of AMR. ABOi KT candidates with high baseline titers need to undergo an intensified preconditioning protocol, including high-dose rituximab (375 mg/m(2)) and intravenous immunoglobulin.
Collapse
Affiliation(s)
- K W Lee
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - J B Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
| | - D K Oh
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - B G Na
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - J Y Choi
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - W T Cho
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - S H Lee
- Department of Surgery, Graduate School, Kyung Hee University, Seoul, Republic of Korea
| | - H J Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - D Cho
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - W S Huh
- Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - S J Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| |
Collapse
|
72
|
Acuna SA, Huang JW, Scott AL, Micic S, Daly C, Brezden-Masley C, Kim SJ, Baxter NN. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am J Transplant 2017; 17:103-114. [PMID: 27575845 DOI: 10.1111/ajt.13978] [Citation(s) in RCA: 116] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Accepted: 07/13/2016] [Indexed: 01/25/2023]
Abstract
Solid organ transplant recipients (SOTRs) are at increased risk of developing and dying from cancer. However, controversies exist around cancer screening in this population owing to reduced life expectancy and competing causes of death. This systematic review assesses the availability, quality and consistency of cancer screening recommendations in clinical practice guidelines (CPGs). We systematically searched bibliographic databases and gray literature to identify CPGs and assessed their quality using AGREE II. Recommendations were extracted along with their supporting evidence. Thirteen guidelines were included in the review. CPGs for kidney recipients were the most frequent source of screening recommendations, and recommendations for skin cancer screening were most frequently presented. Some screening recommendations differed from those for the general population, based on literature demonstrating higher cancer incidence among SOTRs versus direct evidence of screening effectiveness. Relevant stakeholders such as oncology specialists, primary care providers and public health experts were not involved in the formulation of the screening recommendations. In conclusion, although several guidelines make recommendations for cancer screening in SOTRs, the availability of cancer screening recommendations varied considerably by transplanted organ. More studies are required to inform cancer screening recommendations in SOTRs, and guideline development should involve transplant patients, oncologists and cancer screening specialists.
Collapse
Affiliation(s)
- S A Acuna
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.,Department of Surgery, Li Ki Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
| | - J W Huang
- Department of Surgery, Li Ki Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
| | - A L Scott
- Department of Surgery, Li Ki Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
| | - S Micic
- Department of Surgery, Li Ki Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
| | - C Daly
- Department of Surgery, Li Ki Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
| | - C Brezden-Masley
- Division of Hematology/Oncology, St. Michael's Hospital, Toronto, Canada.,Department of Medicine, University of Toronto, Toronto, Canada
| | - S J Kim
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.,Department of Medicine, University of Toronto, Toronto, Canada.,Division of Nephrology and the Kidney Transplant Program, Toronto General Hospital, University Health Network, Toronto, Canada
| | - N N Baxter
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.,Department of Surgery, Li Ki Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.,Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Canada
| |
Collapse
|
73
|
Lee NJ, Chung MS, Jung SC, Kim HS, Choi CG, Kim SJ, Lee DH, Suh DC, Kwon SU, Kang DW, Kim JS. Comparison of High-Resolution MR Imaging and Digital Subtraction Angiography for the Characterization and Diagnosis of Intracranial Artery Disease. AJNR Am J Neuroradiol 2016; 37:2245-2250. [PMID: 27659192 DOI: 10.3174/ajnr.a4950] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 07/22/2016] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE High-resolution MR imaging has recently been introduced as a promising diagnostic modality in intracranial artery disease. Our aim was to compare high-resolution MR imaging with digital subtraction angiography for the characterization and diagnosis of various intracranial artery diseases. MATERIALS AND METHODS Thirty-seven patients who had undergone both high-resolution MR imaging and DSA for intracranial artery disease were enrolled in our study (August 2011 to April 2014). The time interval between the high-resolution MR imaging and DSA was within 1 month. The degree of stenosis and the minimal luminal diameter were independently measured by 2 observers in both DSA and high-resolution MR imaging, and the results were compared. Two observers independently diagnosed intracranial artery diseases on DSA and high-resolution MR imaging. The time interval between the diagnoses on DSA and high-resolution MR imaging was 2 weeks. Interobserver diagnostic agreement for each technique and intermodality diagnostic agreement for each observer were acquired. RESULTS High-resolution MR imaging showed moderate-to-excellent agreement (interclass correlation coefficient = 0.892-0.949; κ = 0.548-0.614) and significant correlations (R = 0.766-892) with DSA on the degree of stenosis and minimal luminal diameter. The interobserver diagnostic agreement was good for DSA (κ = 0.643) and excellent for high-resolution MR imaging (κ = 0.818). The intermodality diagnostic agreement was good (κ = 0.704) for observer 1 and moderate (κ = 0.579) for observer 2, respectively. CONCLUSIONS High-resolution MR imaging may be an imaging method comparable with DSA for the characterization and diagnosis of various intracranial artery diseases.
Collapse
Affiliation(s)
- N J Lee
- From the Department of Radiology and Research Institute of Radiology (N.J.L., M.S.C., S.C.J., H.S.K., C.-G.C., S.J.K., D.H.L., D.C.S.)
| | - M S Chung
- From the Department of Radiology and Research Institute of Radiology (N.J.L., M.S.C., S.C.J., H.S.K., C.-G.C., S.J.K., D.H.L., D.C.S.)
| | - S C Jung
- From the Department of Radiology and Research Institute of Radiology (N.J.L., M.S.C., S.C.J., H.S.K., C.-G.C., S.J.K., D.H.L., D.C.S.)
| | - H S Kim
- From the Department of Radiology and Research Institute of Radiology (N.J.L., M.S.C., S.C.J., H.S.K., C.-G.C., S.J.K., D.H.L., D.C.S.)
| | - C-G Choi
- From the Department of Radiology and Research Institute of Radiology (N.J.L., M.S.C., S.C.J., H.S.K., C.-G.C., S.J.K., D.H.L., D.C.S.)
| | - S J Kim
- From the Department of Radiology and Research Institute of Radiology (N.J.L., M.S.C., S.C.J., H.S.K., C.-G.C., S.J.K., D.H.L., D.C.S.)
| | - D H Lee
- From the Department of Radiology and Research Institute of Radiology (N.J.L., M.S.C., S.C.J., H.S.K., C.-G.C., S.J.K., D.H.L., D.C.S.)
| | - D C Suh
- From the Department of Radiology and Research Institute of Radiology (N.J.L., M.S.C., S.C.J., H.S.K., C.-G.C., S.J.K., D.H.L., D.C.S.)
| | - S U Kwon
- Department of Neurology (S.U.K., D.-W.K., J.S.K.), University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - D-W Kang
- Department of Neurology (S.U.K., D.-W.K., J.S.K.), University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - J S Kim
- Department of Neurology (S.U.K., D.-W.K., J.S.K.), University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| |
Collapse
|
74
|
Ishak CA, Marshall AE, Passos DT, White CR, Kim SJ, Cecchini MJ, Ferwati S, MacDonald WA, Howlett CJ, Welch ID, Rubin SM, Mann MRW, Dick FA. An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences. Mol Cell 2016; 64:1074-1087. [PMID: 27889452 DOI: 10.1016/j.molcel.2016.10.021] [Citation(s) in RCA: 100] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Revised: 08/17/2016] [Accepted: 10/17/2016] [Indexed: 12/21/2022]
Abstract
Repetitive genomic regions include tandem sequence repeats and interspersed repeats, such as endogenous retroviruses and LINE-1 elements. Repressive heterochromatin domains silence expression of these sequences through mechanisms that remain poorly understood. Here, we present evidence that the retinoblastoma protein (pRB) utilizes a cell-cycle-independent interaction with E2F1 to recruit enhancer of zeste homolog 2 (EZH2) to diverse repeat sequences. These include simple repeats, satellites, LINEs, and endogenous retroviruses as well as transposon fragments. We generated a mutant mouse strain carrying an F832A mutation in Rb1 that is defective for recruitment to repetitive sequences. Loss of pRB-EZH2 complexes from repeats disperses H3K27me3 from these genomic locations and permits repeat expression. Consistent with maintenance of H3K27me3 at the Hox clusters, these mice are developmentally normal. However, susceptibility to lymphoma suggests that pRB-EZH2 recruitment to repetitive elements may be cancer relevant.
Collapse
Affiliation(s)
- Charles A Ishak
- London Regional Cancer Program, London, ON N6A 4L6, Canada; Department of Biochemistry, Western University, London, ON N6A 3K7, Canada
| | - Aren E Marshall
- London Regional Cancer Program, London, ON N6A 4L6, Canada; Department of Biochemistry, Western University, London, ON N6A 3K7, Canada
| | - Daniel T Passos
- London Regional Cancer Program, London, ON N6A 4L6, Canada; Department of Biochemistry, Western University, London, ON N6A 3K7, Canada
| | - Carlee R White
- Children's Health Research Institute, London, ON N6A 4L6, Canada; Department of Biochemistry, Western University, London, ON N6A 3K7, Canada
| | - Seung J Kim
- London Regional Cancer Program, London, ON N6A 4L6, Canada; Department of Biochemistry, Western University, London, ON N6A 3K7, Canada
| | - Matthew J Cecchini
- London Regional Cancer Program, London, ON N6A 4L6, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A 3K7, Canada
| | - Sara Ferwati
- London Regional Cancer Program, London, ON N6A 4L6, Canada; Department of Biochemistry, Western University, London, ON N6A 3K7, Canada
| | - William A MacDonald
- Magee-Womens Research Institute, Pittsburgh, PA 15213, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Christopher J Howlett
- Department of Pathology and Laboratory Medicine, Western University, London, ON N6A 3K7, Canada
| | - Ian D Welch
- Animal Care Services, University of British Columbia, Vancouver, BC V6T1Z4, Canada
| | - Seth M Rubin
- Department of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, CA 95064, USA
| | - Mellissa R W Mann
- Magee-Womens Research Institute, Pittsburgh, PA 15213, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Frederick A Dick
- London Regional Cancer Program, London, ON N6A 4L6, Canada; Children's Health Research Institute, London, ON N6A 4L6, Canada; Department of Biochemistry, Western University, London, ON N6A 3K7, Canada.
| |
Collapse
|
75
|
Kim SJ, Han KT, Kim SJ, Park EC. Association Between Results of Quality Assessment of Long-Term Care Facilities and Hospital-Acquired Pneumonia in Individuals with Stroke or Neurodegenerative Disease in Korea. J Am Geriatr Soc 2016; 64:e311-e313. [PMID: 27869297 DOI: 10.1111/jgs.14536] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Seung J Kim
- Department of Public Health, Graduate School, Institute of Health Services Research, Yonsei University, Seoul, Korea
| | - Kyu-Tae Han
- Department of Public Health, Graduate School, Institute of Health Services Research, Yonsei University, Seoul, Korea
| | - Sun J Kim
- Department of Health Administration, Soonchunhyang University, Chungnam, Korea
| | - Eun-Cheol Park
- Institute of Health Services Research, Department of Preventive Medicine, College of Medicine, Yonsei University, Seoul, Korea
| |
Collapse
|
76
|
Lee MH, Jang JH, Min HJ, Jang HI, Nah JH, Lyu CJ, Han KS, Won JH, Lee YH, Chong SY, Mun YC, Lee WS, Kim SJ, Kim I. Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation. Bone Marrow Transplant 2016; 52:258-263. [PMID: 27819689 DOI: 10.1038/bmt.2016.260] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Revised: 08/22/2016] [Accepted: 08/24/2016] [Indexed: 11/09/2022]
Abstract
We performed a retrospective study of 1868 consecutive unrelated donors to predict the risk factors related to general discomfort, limitations in activities of daily living (ADLs) and intention of a second donation in hematopoietic stem cell (HSC) donation. General discomfort and limitations in ADLs were assessed by numerical measurement (scores of 0-10) and donor's intention of a second donation by yes or no reply. The post-donation questionnaires were completed within 48 h after HSC collection and at 1 week, 4 weeks, and 4 months thereafter. Predictors of general discomfort included female sex (P<0.0001), bone marrow (BM) collection (P<0.0001) or PBSC collection through a central line (CL; P=0.0349), 2-day collection (P=0.0150) and negative or undetermined intention of a second donation on day 1 (P<0.0001). Predictors of limitations in ADLs included age group of 30-39 years (P=0.0046), female sex (P<0.0001), BM collection (P<0.0001) or PBSC collection through a CL (P<0.0001) and negative or undetermined intention of a second donation on day 1 (P<0.0001). The only predictor of positive intention of a second donation was male sex (P=0.0007). Age, sex and collection method and period should be considered risk factors when unrelated HSC donation is performed.
Collapse
Affiliation(s)
- M H Lee
- Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, South Korea
| | - J H Jang
- Korea Marrow Donor Program, Seoul, South Korea
| | - H J Min
- Clinical Research Institute, Konkuk University Medical Center, Seoul, South Korea
| | - H I Jang
- Korea Marrow Donor Program, Seoul, South Korea
| | - J H Nah
- Korea Marrow Donor Program, Seoul, South Korea
| | - C J Lyu
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - K-S Han
- Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, South Korea
| | - J H Won
- Department of Hematology-Oncology, Soon Chun Hyang University Hospital, Seoul, South Korea
| | - Y-H Lee
- Department of Pediatrics, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, South Korea
| | - S Y Chong
- Department of Internal Medicine, Bundang Cha Hospital, Seongnam, South Korea
| | - Y C Mun
- Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea
| | - W S Lee
- Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
| | - S J Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - I Kim
- Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
| |
Collapse
|
77
|
Kim SJ, Kim WS. Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al. Ann Oncol 2016; 27:2133-2134. [PMID: 27502713 DOI: 10.1093/annonc/mdw296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S J Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul.,Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea
| | - W S Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul
| |
Collapse
|
78
|
Affiliation(s)
- S J Kim
- Department of Dermatology, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-gu, Suwon, 16499, Korea
| | - Y C Kim
- Department of Dermatology, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-gu, Suwon, 16499, Korea
| |
Collapse
|
79
|
Min J, Park J, Lee YJ, Kim SJ, Park JS, Cho YJ, Yoon HI, Lee CT, Lee JH. Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis 2016; 19:1239-45. [PMID: 26459540 DOI: 10.5588/ijtld.14.0139] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The long-term treatment outcomes of Mycobacterium avium complex (MAC) lung disease (LD) have not been adequately evaluated. OBJECTIVE We evaluated the determinants of microbiological recurrence after successful treatment for MAC LD. DESIGN The medical records of 295 MAC LD patients treated with combination chemotherapy from 2004 to 2013 were reviewed. The clinical data, microbiological study results and chest computerised tomography findings were collected for each patient. RESULTS Ninety-one patients who maintained negative sputum conversion during treatment and had a minimum 10-month follow-up period after treatment were included. The median duration of follow-up was 25 months. Seventy-one (78.0%) patients remained microbiologically disease-free, while 20 (22.0%) had microbiological recurrence after successful treatment. Age, sex and body mass index were not associated with microbiological recurrence. Longer intervals between initial diagnosis and administration of medication (P = 0.024), increased number of involved lobes (P = 0.033) and failure of sputum conversion within 6 months of initiating treatment (P = 0.017) were significantly associated with microbiological recurrence. CONCLUSION Microbiological recurrence after successful anti-MAC chemotherapy was associated with the time interval between initial diagnosis and administration of medication, number of lobes involved and time to sputum conversion during treatment.
Collapse
Affiliation(s)
- J Min
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| | - J Park
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| | - Y J Lee
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| | - S J Kim
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| | - J S Park
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| | - Y-J Cho
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| | - H I Yoon
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| | - C-T Lee
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| | - J H Lee
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea
| |
Collapse
|
80
|
Kim HW, Heo JY, Lee YM, Kim SJ, Jeong HW. Unmasking Granulomatous Pneumocystis jirovecii Pneumonia with Nodular Opacity in an HIV-Infected Patient after Initiation of Antiretroviral Therapy. Yonsei Med J 2016; 57:1042-1046. [PMID: 27189304 PMCID: PMC4951449 DOI: 10.3349/ymj.2016.57.4.1042] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 07/16/2015] [Accepted: 07/20/2015] [Indexed: 11/27/2022] Open
Abstract
Pneumocystis jirovecii pneumonia (PJP) in patients with HIV infection can, in rare cases, present with pulmonary nodules that histologically involve granulomatous inflammation. This report describes an intriguing case of granulomatous PJP with pulmonary nodules after commencing antiretroviral therapy (ART) in an HIV-infected patient without respiratory signs or symptoms. Diagnosis of granulomatous PJP was only achieved through thoracoscopic lung biopsy. This case suggests that granulomatous PJP should be considered in the differential diagnosis of pulmonary nodules in HIV-infected patients for unmasking immune reconstitution inflammatory syndrome manifestation after initiation of ART.
Collapse
Affiliation(s)
- Hyung Woo Kim
- Division of Infectious Diseases, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea
| | - Jung Yeon Heo
- Division of Infectious Diseases, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
| | - Yong Moon Lee
- Department of Pathology, Chungbuk National University Hospital, Cheongju, Korea
| | - S J Kim
- Department of Radiology, Chungbuk National University Hospital, Cheongju, Korea
| | - Hye Won Jeong
- Division of Infectious Diseases, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea
| |
Collapse
|
81
|
Lee SC, Kim KH, Kim OH, Lee SK, Kim SJ. Activation of Autophagy by Everolimus Confers Hepatoprotection Against Ischemia-Reperfusion Injury. Am J Transplant 2016; 16:2042-54. [PMID: 26814830 DOI: 10.1111/ajt.13729] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Revised: 12/16/2015] [Accepted: 01/08/2016] [Indexed: 01/25/2023]
Abstract
As the criteria for liver donation have been extended to include marginal donors, liver grafts are becoming particularly vulnerable to hepatic ischemia-reperfusion injury (IRI). However, no specific measures have been validated to ameliorate hepatic IRI. In this article, we explored whether everolimus has protective effects against hepatic IRI in relation with autophagy. The effects of everolimus were investigated in both in vitro and in vivo hepatic IRI models. Mouse hepatocyte AML12 cells and BALB/c mice were utilized for the establishment of each model. In the IRI-induced AML12 cells, everolimus treatment increased the expressions of autophagic markers (microtubule-associated protein 1 light chain 3 and p62) and decreased pro-apoptotic proteins (cleaved caspase 3 and cleaved poly-ADP ribose polymerase). The blockage of autophagy, using either bafilomycin A1 or si-autophagy-related protein 5, abrogated these anti-apoptosis effects of everolimus. Subsequently, everolimus administration to the hepatic IRI-induced mice provided hepatoprotective effects in terms of (1) decreasing the expressions of pro-apoptotic proteins, (2) inhibiting the release of pro-inflammatory cytokines (IL-6 and tumor necrosis factor-α), (3) reducing elevated liver enzymes (aspartate transaminase, alanine transaminase, and ammonia), and (4) restoring liver histopathology. These findings suggest that everolimus protects the liver against hepatic IRI by way of activating autophagy, and thus could be a potential therapeutic agent for hepatic IRI.
Collapse
Affiliation(s)
- S C Lee
- Department of Surgery, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea
| | - K H Kim
- Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea
| | - O H Kim
- Department of Surgery, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea
| | - S K Lee
- Department of Surgery, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea
| | - S J Kim
- Department of Surgery, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea
| |
Collapse
|
82
|
Sapir-Pichhadze R, Pintilie M, Tinckam KJ, Laupacis A, Logan AG, Beyene J, Kim SJ. Survival Analysis in the Presence of Competing Risks: The Example of Waitlisted Kidney Transplant Candidates. Am J Transplant 2016; 16:1958-66. [PMID: 26751409 DOI: 10.1111/ajt.13717] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2015] [Revised: 12/30/2015] [Accepted: 01/03/2016] [Indexed: 01/25/2023]
Abstract
Competing events (or risks) preclude the observation of an event of interest or alter the probability of the event's occurrence and are commonly encountered in transplant outcomes research. Transplantation, for example, is a competing event for death on the waiting list because receiving a transplant may significantly decrease the risk of long-term mortality. In a typical analysis of time-to-event data, competing events may be censored or incorporated into composite end points; however, the presence of competing events violates the assumption of "independent censoring," which is the basis of standard survival analysis techniques. The use of composite end points disregards the possibility that competing events may be related to the exposure in a way that is different from the other components of the composite. Using data from the Scientific Registry of Transplant Recipients, this paper reviews the principles of competing risks analysis; outlines approaches for analyzing data with competing events (cause-specific and subdistribution hazards models); compares the estimates obtained from standard survival analysis, which handle competing events as censoring events; discusses the appropriate settings in which each of the two approaches could be used; and contrasts their interpretation.
Collapse
Affiliation(s)
- R Sapir-Pichhadze
- Division of Nephrology and the Multi Organ Transplant Program, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada.,Centre for Outcomes Research and Evaluation (CORE), McGill University Health Centre, Montreal, Quebec, Canada.,Division of Nephrology, Department of Medicine, McGill University, Montreal, Quebec, Canada.,Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - M Pintilie
- Division of Biostatistics, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
| | - K J Tinckam
- Division of Nephrology and the Kidney Transplant Program, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.,Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,Departments of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - A Laupacis
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.,Departments of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.,Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada
| | - A G Logan
- Division of Nephrology and the Kidney Transplant Program, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.,Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - J Beyene
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.,Population Health Sciences, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada
| | - S J Kim
- Division of Nephrology and the Kidney Transplant Program, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.,Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,Division of Nephrology and the Renal Transplant Program, St. Michael's Hospital, Toronto, Ontario, Canada
| |
Collapse
|
83
|
Ahn S, Min SK, Min SI, Ha J, Jung IM, Kim SJ, Park HS, Lee T. Treatment Strategy for Persistent Sciatic Artery and Novel Classification Reflecting Anatomic Status. Eur J Vasc Endovasc Surg 2016; 52:360-9. [PMID: 27369291 DOI: 10.1016/j.ejvs.2016.05.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Accepted: 05/06/2016] [Indexed: 10/21/2022]
Abstract
BACKGROUND Persistent sciatic artery (PSA) is a relatively rare congenital variant of the lower limb vasculature and can have highly variable clinical presentations. The purpose of this study was to analyze the relationship between PSA anatomy and clinical presentation, and to suggest an optimal management strategy. METHODS Between 2001 and 2014, 24 PSAs in 19 patients were diagnosed by computed tomography and referred to the vascular surgery department. Patient demographics, types of PSA and femoral artery, aneurysmal changes, symptoms, and treatment methods were assessed. Additionally, all English literature from 1964 to 2014 was reviewed and compared using the PubMed database (224 PSAs in 171 patients). RESULTS PSA was diagnosed in 10 men (52.6%) and nine women (47.4%). PSAs were bilateral in five patients (26.3%) and symptomatic in 12 patients, while in seven patients PSA was found incidentally. According to the Pillet-Gauffre classification, Type 2a was the most common variant (n = 15/24, 62.5%), with unclassifiable types in two limbs. Compared with cases in the literature, the PSA occlusion rate in this study was higher (n = 10/24, 41.7% vs. n = 54/224, 27.5%), but aneurysm incidence was higher in the literature cases (n = 5/24, 20.8% vs. n = 112/224; 50.7%). In this study, 16 limbs (66.6%) were treated conservatively, and six limbs were treated by open surgery, including four bypasses, one amputation, and one thrombo-embolectomy. Endovascular coil embolization was performed in one limb, and a hybrid procedure with stent graft was performed in one limb with PSA aneurysm. Based on the present series and the literature review, a new classification system and treatment option is proposed according to the anatomic status and the presence of aneurysm. According to the new classification, class III was the most common in both the present study (18/24; 75%) and the literature review, and the presence of aneurysm was the most important determinant of surgical treatment. CONCLUSIONS The new classification system is simple and provides guidance for management. Limb anatomy of the femoral artery system and the presence of PSA aneurysm should be considered when selecting the optimal treatment. The risk of embolism from the presence of aneurysm is an important factor for treatment, and bypass surgery is mostly required in classes III and IV.
Collapse
Affiliation(s)
- S Ahn
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S-K Min
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S-I Min
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - J Ha
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - I M Jung
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S J Kim
- Department of Surgery, Seonam University College of Medicine, Goyang-si, Gyeonggi-do, Republic of Korea
| | - H S Park
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - T Lee
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
| |
Collapse
|
84
|
Lee CY, Kim SJ, Park BC, Han JH. Effects of dietary supplementation of bacteriophages against enterotoxigenic Escherichia coli (ETEC) K88 on clinical symptoms of post-weaning pigs challenged with the ETEC pathogen. J Anim Physiol Anim Nutr (Berl) 2016; 101:88-95. [PMID: 27271838 DOI: 10.1111/jpn.12513] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Accepted: 03/12/2016] [Indexed: 11/29/2022]
Abstract
The present study was performed to investigate the effects of dietary supplementation of bacteriophages (phages) against enterotoxigenic Escherichia coli (ETEC) K88 as a therapy against the ETEC infection in post-weaning pigs. Two groups of post-weaning pigs aged 35 days, eight animals per group, were challenged with 3.0 × 1010 colony forming units of ETEC K88, a third group given the vehicle. The unchallenged group and one challenged group were fed a basal nursery diet for 14 days while the remaining challenged group was fed the basal diet supplemented with 1.0 × 107 plaque forming units of the phage per kg. Average daily gain (ADG), goblet cell density and villous height:crypt depth (VH:CD) ratio in the intestine were less in the challenged group than in the unchallenged group within the animals fed the basal diet (p < 0.05); the reverse was true for rectal temperature, faecal consistency score (FCS), E. coli adhesion score (EAS) in the intestine, serum interleukin-8 (IL-8) and tumour necrosis factor-α (TNF-α) concentrations and digesta pH in the stomach, caecum and colon. The ETEC infection symptom within the challenged animals was alleviated by the dietary phage supplementation (p < 0.05) in ADG, FCS, EAS in the jejunum, serum TNF-α concentration, digesta pH in the colon, goblet cell density in the ileum and colon and VH:CD ratio in the ileum. Moreover, the infection symptom tended to be alleviated (p < 0.10) by the phage supplementation in rectal temperature, EAS in the ileum and caecum, and VH:CD ratio in the duodenum and jejunum. However, EAS in the colon, digesta pH in the stomach and caecum, and goblet cell density in the jejunum did not change due to the dietary phage. Overall, results indicate that the phage therapy is effective for alleviation of acute ETEC K88 infection in post-weaning pigs.
Collapse
Affiliation(s)
- C Y Lee
- Regional Animal Industry Center, Gyeongnam National University of Science and Technology, Jinju, Korea
| | - S J Kim
- College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon, Korea
| | - B C Park
- Graduate School of International Agricultural Technology, Seoul National University, Pyeongchang, Korea
| | - J H Han
- College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon, Korea
| |
Collapse
|
85
|
Yoo HY, Kim P, Kim WS, Lee SH, Kim S, Kang SY, Jang HY, Lee JE, Kim J, Kim SJ, Ko YH, Lee S. Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al. Haematologica 2016; 101:e271. [PMID: 27252517 DOI: 10.3324/haematol.2016.148015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- H Y Yoo
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
| | - P Kim
- Ewha Research Center for Systems Biology (ERCSB), Ewha Womans University, Seoul, Korea
| | - W S Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea
| | - S H Lee
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
| | - S Kim
- Ewha Research Center for Systems Biology (ERCSB), Ewha Womans University, Seoul, Korea Department of Bio-Information Science, Ewha Womans University Samsung Medical Center, Sungkyunkwan University, Seoul, Korea
| | - S Y Kang
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea
| | - H Y Jang
- DNA Link Inc, Ewha Womans University, Seoul, Korea
| | - J E Lee
- DNA Link Inc, Ewha Womans University, Seoul, Korea
| | - J Kim
- Department of Life Science, Ewha Womans University, Seoul, Korea
| | - S J Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea
| | - Y H Ko
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea
| | - S Lee
- Ewha Research Center for Systems Biology (ERCSB), Ewha Womans University, Seoul, Korea Department of Bio-Information Science, Ewha Womans University Samsung Medical Center, Sungkyunkwan University, Seoul, Korea Department of Life Science, Ewha Womans University, Seoul, Korea
| |
Collapse
|
86
|
Kim JS, Lee MY, Kim SJ, Jeon SE, Cha I, Hong S, Chung GT, Huh MJ, Kang YH, Yoo CK, Kim J. High-Level Ciprofloxacin-Resistant Campylobacter jejuni Isolates Circulating in Humans and Animals in Incheon, Republic of Korea. Zoonoses Public Health 2016; 63:545-554. [PMID: 27234414 DOI: 10.1111/zph.12262] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Indexed: 11/26/2022]
Abstract
Campylobacter jejuni is one of the major causative pathogens of outbreaks or sporadic cases of diarrhoeal diseases worldwide. In this study, we compared the phenotypic and genetic characteristics of C. jejuni isolates of human and food-producing animal origins in Korea and examined the genetic relatedness between these two groups of isolates. Regardless of isolation source, all C. jejuni isolates harboured four virulence genes, cadF, cdtB, ciaB and racR, whereas the wlaN and virB11 genes were more frequently observed in human isolates. Antimicrobial susceptibility testing showed that the majority of C. jejuni isolates displayed high-level resistance to fluoroquinolone (95.2%) or tetracycline (76.2%) antibiotics, and 12.4% of isolates exhibited multidrug resistance (more than three classes of antibiotics tested). Pulsed-field gel electrophoresis (PFGE) of all Campylobacter isolates revealed 51 different SmaI-PFGE patterns and six major clusters containing both human and animal isolates. These results indicate that genetically diverse strains of C. jejuni with antimicrobial drug-resistance and virulence properties have prevailed in Incheon. Nevertheless, some particular populations continue to circulate within the community, providing the evidence for an epidemiological link of C. jejuni infections between humans and food-producing animals. Therefore, the continued monitoring and surveillance of C. jejuni isolates of human and food-producing animal origins are required for public health and food safety.
Collapse
Affiliation(s)
- J S Kim
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea
| | - M Y Lee
- Incheon Institute of Public Health and Environment Research, Jung-gu, Incheon, Korea
| | - S J Kim
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea
| | - S-E Jeon
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea
| | - I Cha
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea
| | - S Hong
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea
| | - G T Chung
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea
| | - M-J Huh
- Incheon Institute of Public Health and Environment Research, Jung-gu, Incheon, Korea
| | - Y-H Kang
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea
| | - C-K Yoo
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea
| | - J Kim
- Division of Enteric Diseases, Center for Infectious Diseases, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Korea.
| |
Collapse
|
87
|
Lee H, Park YK, Kim SJ, Kim BJ, An KH, Kim BH, Jung SC. Facile Synthesis of Iron Oxide/Graphene Nanocomposites Using Liquid Phase Plasma Method. J Nanosci Nanotechnol 2016; 16:4483-4486. [PMID: 27483778 DOI: 10.1166/jnn.2016.10995] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Liquid phase plasma (LPP) method was applied, for the first time, to the impregnation of iron oxide nanoparticles onto graphene sheet. Iron oxide nanoparticles with the size of 50 nm were precipitated with uniform dispersion on the surface of graphene sheet. The amount of iron oxide nanoparticles precipitated on graphene sheets increased with increasing LPP process times. The XPS, Raman and EDX analyses showed that the iron oxide/graphene composites synthesized by the LPP process.
Collapse
|
88
|
Choi JS, Lee H, Park YK, Kim SJ, Kim BJ, An KH, Kim BH, Jung SC. Application of Silver and Silver Oxide Nanoparticles Impregnated on Activated Carbon to the Degradation of Bromate. J Nanosci Nanotechnol 2016; 16:4493-4497. [PMID: 27483780 DOI: 10.1166/jnn.2016.10986] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Silver and silver oxide nanoparticles were impregnated on the surface of powdered activated carbon (PAC) using a single-step liquid phase plasma (LPP) method. Spherical silver and silver oxide nanoparticles of 20 to 100 nm size were dipersed evenly on the surface of PAC. The impregnated PAC exhibited a higher activity for the decomposition of bromate than bare PAC. The XPS, Raman and EDX analyses showed that the Ag/PAC composites synthesized by the LPP process.
Collapse
|
89
|
Shimoda M, Chihara Y, Kagara N, Naoi Y, Shimomura A, Shimazu K, Kim SJ, Noguchi S. Abstract P3-06-05: Importance of TGFβ-SMAD3 axis in resistance to anti-HER2 drugs. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-06-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim: The aim of this study was to elucidate the role of transforming growth factor β (TGFβ) in the resistance of HER2-positive breast cancer cells to anti-HER2 drugs including trastuzumab and lapatinib.
Methods: A HER2-positive breast cancer cell line, SKBR3, was cultured in the presence or absence of TGFβ for 14 days. Subsequently, TGFβ-treated cells were cultured for seven days with or without the anti-HER2 drugs. Sensitivity to trastuzumab and lapatinib was estimated by the WST-8 cell viability assay or absolute cell counts using In Cell Analyzer (GE Healthcare). Proportion of CD44+ CD24– breast cancer stem cells was estimated by flow cytometry of cells immunostained with anti-CD44 and anti-CD24 antibodies. For clinical study, 33 patients with HER2-positive breast cancer receiving neoadjuvant paclitaxel plus trastuzumab in our institution were analyzed. Among the cases, 27 biopsy samples obtained before any treatment from 27 patients who completed 12 cycles of weekly paclitaxel and trastuzumab were subjected to CD24 immunohistochemistry.
Results: SKBR3 cells cultured with TGFβ for 14 days exhibited decreased sensitivity to both trastuzumab and lapatinib. Time course study revealed that continuous stimulation for 14 days with TGFβ was required for the resistance to anti-HER2 drugs. Activation of SMAD3, a downstream target molecule of TGFβ, was enhanced over time, judged by the increase in phosphorylation and in nuclear translocation. During 14 day culture with TGFβ, proportion of CD44+ CD24– cells were dramatically increased, and mammosphere formation, another marker of breast cancer stem cells, was significantly enhanced compared to cells treated without TGFβ. Among four HER2-positive breast cancer cell lines, only SKBR3 cells showed increased proportion of CD44+ CD24– cells and resistance to the anti-HER2 drugs, while other two cell lines exhibited epithelial-mesenchymal transition (EMT) in response to TGFβ. To explore the possibility of targeting TGFβ-SMAD3 axis to overcome resistance to anti-HER2 therapy, we used SIS3, a specific inhibitor of SMAD3. Importantly, SIS3 completely restored the sensitivity to both trastuzumab and lapatinib of TGFβ-treated SKBR3 cells, with the decrease in the proportion of CD44+ CD24– cells. These in vitro results suggest that CD24 downregulation can be a surrogate marker of resistance to anti-HER2 therapy. To establish this, we evaluated the CD24 expression in tumor samples of breast cancer patients who received paclitaxel plus trastuzumab in the neoadjuvant setting. Weak CD24 expression in tumor cells in biopsy samples obtained before any treatment was significantly correlated with poorer response to the drugs.
Conclusion: These data clearly indicate the importance of TGFβ-SMAD3 axis in the acquired resistance to anti-HER2 drugs. Moreover, resistance to anti-HER2 therapy is associated with the property of breast cancer stem cells rather than EMT. Targeting TGFβ-SMAD3 axis warrants further investigation for overcoming resistance to anti-HER2 therapeutics.
Citation Format: Shimoda M, Chihara Y, Kagara N, Naoi Y, Shimomura A, Shimazu K, Kim SJ, Noguchi S. Importance of TGFβ-SMAD3 axis in resistance to anti-HER2 drugs. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-06-05.
Collapse
Affiliation(s)
- M Shimoda
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Y Chihara
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - N Kagara
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Y Naoi
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - A Shimomura
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - K Shimazu
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - SJ Kim
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - S Noguchi
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| |
Collapse
|
90
|
Kaise H, Ishikawa T, Miura D, Hasegawa Y, Horiguchi J, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Suzuki M, Taguchi T, Akazawa K, Kohno N. Abstract P3-07-50: Early and accurate prediction of pathological response by magnetic resonance imaging and ultrasonography in patients undergoing neoadjuvant chemotherapy for operable breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NAC) reduces tumor size, and increases the frequency of breast-conserving surgery in operable breast cancers. Response predictions to NAC are made based on diagnostic imaging.
Although various studies have reported the optimal timing for diagnostic imaging, this still remains unclear.
Purpose: To identify the optimal timing of diagnostic imaging for the response prediction to NAC, and to evaluate the accuracy of response prediction.
Methods: We evaluated 146 cases enrolled in the JONIE-1 study (a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a NAC in patients with HER2-negative primary breast cancer). The chemotherapy regimen was FEC100×4 courses followed by weekly paclitaxel 80×12 courses (± zoledronic acid). Statistical analysis of the association between the tumor reduction ratio and the histopathological response and the prediction of pathological complete response (pCR) was performed using JMP software. The maximum tumor diameter was evaluated using magnetic resonance imaging and ultrasound on each patient 3 times (before NAC, after FEC treatment, after NAC) and tumor reduction ratios were calculated.
Results: The average age of the patients was 49.8 years old. The menopause status was pre-menopause in 84 patients, and post-menopause in 58 patients. Regarding the subtype classification, 116 patients were of the luminal type (Lum) and 26 patients were triple negative (TN), and the Ki-67 labeling index had a median of 25% (1%-93%).
Pathological examination demonstrated that 16 patients had pCR(11.3%, Lum, 9;TN: 7), and 126 patients had non-pCR (88.7%, Lum:107; TN:19). Seven patients had clinical-CR (4.8%, Lum: 4; TN: 3) at post-FEC, and 26 patients (17.8%, Lum: 20; TN: 6) at post-NAC. The prediction of pCR at post-FEC and post-NAC was evaluated by single variable analysis, resulting in an AUC (0.75645) p=0.0017 at post-FEC, and AUC (0.76563) p=0.0001 at post-NAC. The sensitivity / specificity / positive predictive value / negative predictive value were 0.625 / 0.873 / 0.385 / 0.948 at post-FEC, 0.250 / 0.976 / 0.571 / 0.911 at post-NAC, respectively. In TN cases, the values were 0.714 / 0.947 / 0.833 / 0.900 in post-FEC, and 0.429 / 1.000 / 1.000 / 0.826 in post-NAC.
Conclusions: Diagnostic imaging evaluation performed after FEC treatment was useful for the prediction of pCR. Furthermore, the reliability was high in Triple Negative Sub type, but is affected by the existence of residual tumors in Luminal type.
Citation Format: Kaise H, Ishikawa T, Miura D, Hasegawa Y, Horiguchi J, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Suzuki M, Taguchi T, Akazawa K, Kohno N. Early and accurate prediction of pathological response by magnetic resonance imaging and ultrasonography in patients undergoing neoadjuvant chemotherapy for operable breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-50.
Collapse
Affiliation(s)
- H Kaise
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - T Ishikawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - D Miura
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - Y Hasegawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - J Horiguchi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Hayashi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - S Takao
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - SJ Kim
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - H Tanino
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Miyashita
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Konishi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - Y Shigeoka
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - K Yamagami
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Suzuki
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - T Taguchi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - K Akazawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - N Kohno
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| |
Collapse
|
91
|
Kim SJ, Kang IJ, Shin MK, Jeong KH, Baek JH, Koh JS, Lee SJ. Impact of chemical peeling combined with negative pressure on human skin. Int J Cosmet Sci 2016; 38:440-3. [PMID: 26832852 DOI: 10.1111/ics.12307] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 01/22/2016] [Indexed: 01/03/2023]
Abstract
OBJECTIVE In vivo changes in skin barrier function after chemical peeling with alpha hydroxyacids (AHAs) have been previously reported. However, the additional effects of physical treatment with chemical agents on skin barrier function have not been adequately studied. This study measured the degree of acute skin damage and the time required for skin barrier repair using non-invasive bioengineering methods in vivo with human skin to investigate the additional effect of a 4% AHA chemical jet accelerated at supersonic velocities. METHODS Thirteen female subjects (average age: 29.54 ± 4.86 years) participated in this study. The faces of the subjects were divided into half according to the block randomization design and were then assigned to receive AHA peeling alone or AHA peeling combined with pneumatic pressure on each side of the face. Transepidermal water loss (TEWL), skin colour and skin blood flow were evaluated at baseline and at 30 min, 2, 5 and 7 days after treatment. RESULTS The TEWL and skin blood flow were significantly increased after 30 min in chemodermabrasion compared with chemical peeling alone (P < 0.05). The TEWL and skin blood flow recovered to baseline after 2 days, and TEWL was significantly decreased at 7 days compared with chemical peeling alone (P < 0.05). CONCLUSIONS Chemodermabrasion can temporarily impair skin barriers, but it is estimated that it can enhance the skin barrier function after 7 days compared to the use of a chemical agent alone. In addition, chemodermabrasion has a more effective impact in the dermis and relatively preserves the skin barrier.
Collapse
Affiliation(s)
- S J Kim
- Dermapro Skin Research Center, DERMAPRO LTD., Seoul, Korea
| | - I J Kang
- Department of Dermatology, College of Medicine, Kyung Hee University, Hoeki-Dong, Dongdaemun-Ku, Seoul, 130-702, Korea
| | - M K Shin
- Department of Dermatology, College of Medicine, Kyung Hee University, Hoeki-Dong, Dongdaemun-Ku, Seoul, 130-702, Korea. ,
| | - K H Jeong
- Department of Dermatology, College of Medicine, Kyung Hee University, Hoeki-Dong, Dongdaemun-Ku, Seoul, 130-702, Korea
| | - J H Baek
- Dermapro Skin Research Center, DERMAPRO LTD., Seoul, Korea
| | - J S Koh
- Dermapro Skin Research Center, DERMAPRO LTD., Seoul, Korea
| | - S J Lee
- Arumdaun Nara Dermatologic Clinic, Seoul, Korea
| |
Collapse
|
92
|
Dung TH, Le TD, Eom KD, Kim SJ, Yoo H. Preparation of Pluronic Grafted Dendritic alpha,epsilon-poly(L-lysine)s and Characterization as a Delivery Adjuvant of Antisense Oligonucleotide. J Nanosci Nanotechnol 2016; 16:1370-1374. [PMID: 27433588 DOI: 10.1166/jnn.2016.11927] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
A series of pluronic grafted dendritic alpha,epsilon-poly(L-lysine)s (DPL-PF127) were synthesized by a conjugation reaction and evaluated the potential use of DPL-PF127 as a delivery agent of antisense oligonucleotide into A375 B3 cells. The structural features of the DPL-PF127 were identified by NMR and FT-IR. The number of pluronic F127 on DPL surface, determined by fluorescamine assay, increased proportionally to the mole ratio between DPL and activated PF127 in reaction. DPL- PF127 showed the physical properties of decrease in zetapotential and increase in size as the mole ratio of PF127 to DPL increased. The complex formation of DPL-PF127 with oligonucleotide was confirmed by running capillary zone electrophoresis (CZE) and agarose gel electrophoresis. DPL-PF127, prepared at the mole ratio of 1:10 in reaction, was the most suitable as a delivery adjuvant of oligonucleotide. In addition, DPL-PF127/oligonucleotide complexes were taken into A375B3 cell without cellular toxicity and delivered antisense oligonucleotide into cell.
Collapse
|
93
|
Singh SK, Kim SJ, Smail N, Schiff J, Paraskevas S, Cantarovich M. Outcomes of Recipients With Pancreas Transplant Alone Who Develop End-Stage Renal Disease. Am J Transplant 2016; 16:535-40. [PMID: 26523479 DOI: 10.1111/ajt.13494] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2015] [Revised: 07/20/2015] [Accepted: 08/15/2015] [Indexed: 01/25/2023]
Abstract
Recipients of pancreas transplant alone (PTA) may be at increased risk for developing end-stage renal disease (ESRD). The survival experience of PTA recipients developing ESRD has not been described. Furthermore, the relative survival of these patients as compared to diabetics on chronic dialysis is unknown. We studied all adult PTA recipients from January 1, 1990 to September 1, 2008 using the Scientific Registry of Transplant Recipients. Each PTA recipient developing ESRD was matched to 10 diabetics on chronic dialysis from the United States Renal Data System. Cox proportional hazards models were fitted to determine the relation between ESRD and mortality among PTA recipients, and the relation between PTA and mortality among diabetics on chronic dialysis. There were 1597 PTA recipients in the study, of which 207 developed ESRD. Those with ESRD had a threefold increase in mortality versus those without (adjusted hazard ratio 3.28 [95% confidence interval: 2.27, 4.76]). There was no significant difference in the risk of death among PTA recipients with ESRD versus diabetics on dialysis. PTA recipients developing ESRD are three times more likely to die than PTA recipients without ESRD; however, the risk of death in these patients was similar to diabetics on chronic dialysis without PTA.
Collapse
Affiliation(s)
- S K Singh
- Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.,Division of Nephrology and the Multi-Organ Transplant Program, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
| | - S J Kim
- Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.,Division of Nephrology and the Multi-Organ Transplant Program, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
| | - N Smail
- Division of Nephrology and the Multi-Organ Transplant Program, McGill University Health Center, McGill University, Montreal, Quebec, Canada
| | - J Schiff
- Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,Division of Nephrology and the Multi-Organ Transplant Program, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
| | - S Paraskevas
- Department of Surgery, Multi-Organ Transplant Program, McGill University Health Center, McGill University, Montreal, Quebec, Canada
| | - M Cantarovich
- Division of Nephrology and the Multi-Organ Transplant Program, McGill University Health Center, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
94
|
Lee HS, Lee JG, Yeom HJ, Chung YS, Kang B, Hurh S, Cho B, Park H, Hwang JI, Park JB, Ahn C, Kim SJ, Yang J. The Introduction of Human Heme Oxygenase-1 and Soluble Tumor Necrosis Factor-α Receptor Type I With Human IgG1 Fc in Porcine Islets Prolongs Islet Xenograft Survival in Humanized Mice. Am J Transplant 2016; 16:44-57. [PMID: 26430779 DOI: 10.1111/ajt.13467] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Revised: 07/05/2015] [Accepted: 07/22/2015] [Indexed: 02/06/2023]
Abstract
Apoptosis during engraftment and inflammation induce poor islet xenograft survival. We aimed to determine whether overexpression of human heme oxygenase-1 (HO-1) or soluble tumor necrosis factor-α receptor type I with human IgG1 Fc (sTNF-αR-Fc) in porcine islets could improve islet xenograft survival. Adult porcine islets were transduced with adenovirus containing human HO-1, sTNF-αR-Fc, sTNF-αR-Fc/HO-1 or green fluorescent protein (control). Humanized mice were generated by injecting human cord blood-derived CD34(+) stem cells into NOD-scid-IL-2Rγ(null) mice. Both HO-1 and sTNF-αR-Fc reduced islet apoptosis under in vitro hypoxia or cytokine stimuli and suppressed RANTES induction without compromising insulin secretion. Introduction of either gene into islets prolonged islet xenograft survival in pig-to-humanized mice transplantation. The sTNF-αR-Fc/HO-1 group showed the best glucose tolerance. Target genes were successfully expressed in islet xenografts. Perigraft infiltration of macrophages and T cells was suppressed with decreased expression of RANTES, tumor necrosis factor-α and IL-6 in treatment groups; however, frequency of pig-specific interferon-γ-producing T cells was not decreased, and humoral response was not significant in any group. Early apoptosis of islet cells was suppressed in the treatment groups. In conclusion, overexpression of HO-1 or sTNF-αR-Fc in porcine islets improved islet xenograft survival by suppressing both apoptosis and inflammation. HO-1 or sTNF-αR-Fc transgenic pigs have potential for islet xenotransplantation.
Collapse
Affiliation(s)
- H-S Lee
- Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Republic of Korea
| | - J-G Lee
- Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - H J Yeom
- Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y S Chung
- Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Republic of Korea
| | - B Kang
- Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S Hurh
- Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - B Cho
- Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - H Park
- Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Republic of Korea.,Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - J I Hwang
- Graduate School of Medicine, Korea University, Seoul, Republic of Korea
| | - J B Park
- Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Republic of Korea.,Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - C Ahn
- Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.,Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.,Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea
| | - S J Kim
- Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Republic of Korea.,Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - J Yang
- Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.,Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
95
|
Kim SJ, Kim MJ, Kim TH. Three-dimensional transperineal ultrasound: is there a correlation among age, weight, delivery mode, and a change in the pelvic floor architecture in Korean premenopausal women? CLIN EXP OBSTET GYN 2016; 43:857-861. [PMID: 29944238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
PURPOSE The purpose of this study was to evaluate the morphological characteristics and related factors of changes to the female pelvic floor architecture during rest and the Valslva maneuver using three-dimensional (3D) transperineal ultrasonography (TPUS) in parous women. MATERIALS AND METHODS One hundred thirty-five premenopausal parous women (aged 29-50 years) were evaluated. The pelvic floor structures were measured during rest and during the Valsalva maneuver using 3D TPUS. RESULTS The delivery mode was an im- portant affecting factor in determining the change of contractility of pelvic floor architecture. The factors of age and weight were asso- ciated with changes in the anus. CONCLUSION The delivery mode might be a meaningful factor in the change of contractility of pelvic floor architecture. These measurements provide a baseline upon which further investigations in a larger cohort of subjects can be compared, to determine the range and change of the normal appearance of the specific pelvic structures.
Collapse
|
96
|
Kim SJ, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol 2015; 27:508-13. [PMID: 26658891 DOI: 10.1093/annonc/mdv596] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2015] [Accepted: 11/21/2015] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Romidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However, the efficacy and safety of romidepsin has never been studied in patients with relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKTL). PATIENTS AND METHODS We conducted an open-label, prospective pilot study to evaluate the efficacy and feasibility of romidepsin in the treatment of patients with ENKTL. The treatment was intravenous infusion of romidepsin (14 mg/m(2)) for 4 h on days 1, 8, and 15 of a 28-day cycle, and was repeated until disease progression or the occurrence of unacceptable toxicity. RESULTS A total of five patients enrolled on to this pilot study. However, three patients developed fever and elevated liver enzyme and bilirubin levels immediately after their first administration of romidepsin. We suspected that these events were associated with Epstein-Barr virus (EBV) reactivation because of the rapidly elevated EBV DNA titers in blood from these patients. An in vitro study with the ENKTL cell line SNK-6 cells also showed that HDAC inhibitors including romidepsin increased the copy number of EBV DNA in a dose-dependent manner. These findings suggested that romidepsin-induced histone acetylation reversed the repressed state of the genes required for EBV reactivation and that romidepsin treatment may have caused EBV reactivation in EBV-infected tumor cells in ENKTL patients. Therefore, we discontinued the enrollment of patients into this pilot study. CONCLUSIONS Our study suggests that the use of romidepsin may cause severe EBV reactivation in patients with ENKTL.
Collapse
Affiliation(s)
- S J Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul
| | - J H Kim
- Samsung Biomedical Research Institute, Samsung Medical Center, Seoul
| | - C S Ki
- Departments of Laboratory Medicine and Genetics
| | - Y H Ko
- Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - J S Kim
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul
| | - W S Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
97
|
Yang SS, Choi JY, Cho WT, Park JB, Kim SJ. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). Transplant Proc 2015; 47:617-21. [PMID: 25891697 DOI: 10.1016/j.transproceed.2014.12.042] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Accepted: 12/31/2014] [Indexed: 12/24/2022]
Abstract
BACKGROUND Compliance with immunosuppressive regimens may affect clinical outcomes in renal transplant recipients. The aim of this study was to assess the safety and efficacy of standard-dose tacrolimus modified-release (TAC-MR) once daily versus tacrolimus (TAC) twice daily in stable renal transplant recipients. METHODS Ninety-nine stable renal transplant recipients were randomized to receive standard-dose tacrolimus twice daily or standard-dose modified-release tacrolimus once daily on a 1:1 (mg:mg) basis. The primary end point was the incidence of adverse events (AEs) in both groups. Secondary end points included biopsy-proven acute rejection, graft survival, patient survival, clinical indicators, and change in score of questionnaire. RESULTS The incidence of AEs was not different between the TAC and TAC-MR groups (56.0% vs 53.1%, P > .05). There were no significant differences in mean calculated glomerular filtration rate, blood pressure, glycosylated hemoglobulin (HbA1c), blood concentration of tacrolimus, and drug compliance. The scores of all items in the 36-item short form health survey (SF-36) were not different between groups, except for vitality. With respect to the subject questionnaire, there was no difference in question scores between the two treatment groups. CONCLUSION A regimen of TAC-MR once daily can be considered as an effective and safe alternative formulation of tacrolimus in stable renal transplant patients.
Collapse
Affiliation(s)
- S-S Yang
- Department of Surgery, Chungnam National University Hospital, Daejeon, Korea
| | - J-Y Choi
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - W-T Cho
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J B Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S J Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
| |
Collapse
|
98
|
Nam Y, Jung J, Park SS, Kim SJ, Shin SJ, Choi JH, Kim M, Yoon HE. Disseminated mucormycosis with myocardial involvement in a renal transplant recipient. Transpl Infect Dis 2015; 17:890-6. [PMID: 26538076 DOI: 10.1111/tid.12452] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Revised: 08/05/2015] [Accepted: 08/13/2015] [Indexed: 12/20/2022]
Abstract
We report the case of a renal transplant recipient with pulmonary and splenic mucormycosis whose demise was accelerated by a myocardial abscess. Once pulmonary and splenic mucormycosis was diagnosed, liposomal amphotericin B was started and immunosuppressant treatments were discontinued. The pulmonary cavities regressed during treatment, but new myocardial and peri-allograft abscesses developed. The myocardial abscess diffusely infiltrated the left ventricular wall and was associated with akinesia, which led to sudden cardiac arrest. This case demonstrates a rare manifestation of mucormycosis and highlights the fatality and invasiveness of this infection.
Collapse
Affiliation(s)
- Y Nam
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, Korea
| | - J Jung
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, Korea
| | - S S Park
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, Korea
| | - S J Kim
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, Korea.,Division of Nephrology, Department of Internal Medicine, Incheon St. Mary's Hospital, Incheon, Korea
| | - S J Shin
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, Korea.,Division of Nephrology, Department of Internal Medicine, Incheon St. Mary's Hospital, Incheon, Korea
| | - J H Choi
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, Korea.,Division of Infectious Disease, Department of Internal Medicine, Incheon St. Mary's Hospital, Incheon, Korea
| | - M Kim
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, Korea.,Division of Cardiology, Department of Internal Medicine, Incheon St. Mary's Hospital, Incheon, Korea
| | - H E Yoon
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, Korea.,Division of Nephrology, Department of Internal Medicine, Incheon St. Mary's Hospital, Incheon, Korea
| |
Collapse
|
99
|
Shin JS, Kim JM, Kim JS, Min BH, Kim YH, Kim HJ, Jang JY, Yoon IH, Kang HJ, Kim J, Hwang ES, Lim DG, Lee WW, Ha J, Jung KC, Park SH, Kim SJ, Park CG. Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. Am J Transplant 2015; 15:2837-50. [PMID: 26096041 DOI: 10.1111/ajt.13345] [Citation(s) in RCA: 130] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 04/02/2015] [Accepted: 04/04/2015] [Indexed: 01/25/2023]
Abstract
Pig islets are an alternative source for islet transplantation to treat type 1 diabetes (T1D), but reproducible curative potential in the pig-to-nonhuman primate (NHP) model has not been demonstrated. Here, we report that pig islet grafts survived and maintained normoglycemia for >6 months in four of five consecutive immunosuppressed NHPs. Pig islets were isolated from designated pathogen-free (DPF) miniature pigs and infused intraportally into streptozotocin-induced diabetic rhesus monkeys under pretreatment with cobra venom factor (CVF), anti-thymocyte globulin (ATG) induction and maintenance with anti-CD154 monoclonal antibody and low-dose sirolimus. Ex vivo expanded autologous regulatory T cells were adoptively transferred in three recipients. Blood glucose levels were promptly normalized in all five monkeys and normoglycemia (90-110 mg/dL) was maintained for >6 months in four cases, the longest currently up to 603 days. Intravenous glucose tolerance tests during the follow-up period showed excellent glucose disposal capacity and porcine C-peptide responses. Adoptive transfer of autologous regulatory T cells was likely to be associated with more stable and durable normoglycemia. Importantly, the recipients showed no serious adverse effects. Taken together, our results confirm the clinical feasibility of pig islet transplantation to treat T1D patients without the need for excessive immunosuppressive therapy.
Collapse
Affiliation(s)
- J S Shin
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea.,Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.,Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - J M Kim
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea.,Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - J S Kim
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea.,Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.,Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - B H Min
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea
| | - Y H Kim
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea.,Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - H J Kim
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea.,Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.,Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
| | - J Y Jang
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea
| | - I H Yoon
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea.,Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - H J Kang
- Department of Laboratory Medicine, Hallym University College of Medicine, Anyang, Korea
| | - J Kim
- Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - E S Hwang
- Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - D G Lim
- National Medical Centre, Seoul, Korea
| | - W W Lee
- Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.,Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
| | - J Ha
- Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
| | - K C Jung
- Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
| | - S H Park
- Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
| | - S J Kim
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea.,Myong-Ji Hospital, Koyang-si, Kyeonggi-do, Korea
| | - C G Park
- Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea.,Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.,Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.,Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.,Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
100
|
Jung HH, Kim SJ, Roh D, Chang JG, Chang WS, Kweon EJ, Kim CH, Chang JW. Bilateral thermal capsulotomy with MR-guided focused ultrasound for patients with treatment-refractory obsessive-compulsive disorder: a proof-of-concept study. Mol Psychiatry 2015; 20:1205-11. [PMID: 25421403 DOI: 10.1038/mp.2014.154] [Citation(s) in RCA: 120] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 09/29/2014] [Accepted: 10/08/2014] [Indexed: 11/09/2022]
Abstract
Despite optimal pharmacotherapy and cognitive-behavioral treatments, a proportion of patients with obsessive-compulsive disorder (OCD) remain refractory to treatment. Neurosurgical ablative or nondestructive stimulation procedures to treat these refractory patients have been investigated. However, despite the potential benefits of these surgical procedures, patients show significant surgery-related complications. This preliminary study investigated the use of bilateral thermal capsulotomy for patients with treatment-refractory OCD using magnetic resonance-guided focused ultrasound (MRgFUS) as a novel, minimally invasive, non-cranium-opening surgical technique. Between February and May 2013, four patients with medically refractory OCD were treated with MRgFUS to ablate the anterior limb of the internal capsule. Patients underwent comprehensive neuropsychological evaluations and imaging at baseline, 1 week, 1 month and 6 months following treatment. Outcomes were measured with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the Hamilton Rating Scale for Depression (HAM-D) and the Hamilton Rating Scale for Anxiety (HAM-A), and treatment-related adverse events were evaluated. The results showed gradual improvements in Y-BOCS scores (a mean improvement of 33%) over the 6-month follow-up period, and all patients showed almost immediate and sustained improvements in depression (a mean reduction of 61.1%) and anxiety (a mean reduction of 69.4%). No patients demonstrated any side effects (physical or neuropsychological) in relation to the procedure. In addition, there were no significant differences found in the comprehensive neuropsychological test scores between the baseline and 6-month time points. This study demonstrates that bilateral thermal capsulotomy with MRgFUS can be used without inducing side effects to treat patients with medically refractory OCD. If larger trials validate the safety, effectiveness and long-term durability of this new approach, this procedure could considerably change the clinical management of treatment-refractory OCD.
Collapse
Affiliation(s)
- H H Jung
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea
| | - S J Kim
- Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea
| | - D Roh
- Department of Psychiatry, Chunchon Sacred Heart Hospital, Hallym University College of Medicine, Chunchon, Korea
| | - J G Chang
- Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea
| | - W S Chang
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea
| | - E J Kweon
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea
| | - C-H Kim
- Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea
| | - J W Chang
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|